

# Northumbria Research Link

Citation: George, Vazhappilly Cijo, Ansari, Shabbir Ahmed, Chelakkot, Vipin Shankar, Chelakkot, Ayshwarya Lakshmi, Chelakkot, Chaithanya, Menon, Varsha, Ramadan, Wafaa, Ethiraj, Kannatt Radhakrishnan, El-Awady, Raafat, Mantso, Theodora, Mitsiogianni, Melina, Panagiotidis, Mihalís, Dellaire, Graham and Vasantha Rupasinghe, H.P. (2019) DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer. *Mutation Research/Reviews in Mutation Research*, 780. pp. 92-105. ISSN 1383-5742

Published by: Elsevier

URL: <https://doi.org/10.1016/j.mrrev.2018.06.001> <<https://doi.org/10.1016/j.mrrev.2018.06.001>>

This version was downloaded from Northumbria Research Link: <http://nrl.northumbria.ac.uk/36887/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)



**Northumbria  
University**  
NEWCASTLE



University**Library**

1 **Review**

2 **DNA-dependent protein kinase:**

3 **Epigenetic alterations and the role in genomic stability of cancer**

4  
5 Vazhappilly Cijo George<sup>1,2</sup>, Shabbir Ansari<sup>3</sup>, Vipin Shankar Chelakkot<sup>4</sup>, Ayshwarya Lakshmi Chelakkot<sup>5</sup>,  
6 Chaithanya Chelakkot<sup>6</sup>, Varsha Menon<sup>2</sup>, Wafaa Ramadan<sup>2,7</sup>, Kannatt Radhakrishnan Ethiraj<sup>8</sup>, Raafat El-  
7 Awady<sup>2,9,10</sup>, Theodora Mantso<sup>11</sup>, Melina Mitsiogianni<sup>11</sup>, Mihalios I. Panayiotidis<sup>11</sup>, Graham Dellaire<sup>12</sup>, H.P.  
8 Vasantha Rupasinghe<sup>1, 12, \*</sup>

9  
10 <sup>1</sup>Department of Plant, Food, and Environmental Sciences, Faculty of Agriculture, Dalhousie University, Truro, NS,  
11 Canada

12 <sup>2</sup>Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates

13 <sup>3</sup>Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler,  
14 Texas, United States of America

15 <sup>4</sup>Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's,  
16 Newfoundland, Canada

17 <sup>5</sup>Duke-NUS Medical School, Singapore

18 <sup>6</sup>Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang,  
19 Korea

20 <sup>7</sup>College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

21 <sup>8</sup>School of Advanced Sciences, VIT University, Vellore, India

22 <sup>9</sup>College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates

23 <sup>10</sup>Cancer Biology Department, National Cancer Institute and College of Medicine, Cairo University, Cairo, Egypt

24 <sup>11</sup>Department of Applied Sciences, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon  
25 Tyne, United Kingdom

26 <sup>12</sup>Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada

\*To whom correspondence should be addressed: Tel: +1 902 893 6623. Fax: +1 902 893 1404.

E-mail: vrupasinghe@dal.ca.

## **Abstract**

DNA-dependent protein kinase (DNA-PK), a member of phosphatidylinositol-kinase family, is a key protein in mammalian DNA double-strand break (DSB) repair that helps to maintain genomic integrity. DNA-PK also plays a central role in immune cell development and protects telomerase during cellular aging. Epigenetic deregulation due to endogenous and exogenous factors may affect the normal function of DNA-PK, which in turn could impair DNA repair and contribute to genomic instability. Recent studies implicate a role for epigenetics in the regulation of DNA-PK expression in normal and cancer cells, which may impact cancer progression and metastasis as well as provide opportunities for treatment and use of DNA-PK as a novel cancer biomarker. In addition, several small molecules and biological agents have been recently identified that can inhibit DNA-PK function or expression, and thus hold promise for cancer treatments. This review discusses the impact of epigenetic alterations and the expression of DNA-PK in relation to the DNA repair mechanisms with a focus on its differential levels in normal and cancer cells.

**Keywords:** DNA-PK, Genomic stability, DNA repair, DNA damage, Epigenetic alternations, Cancer

50    **Abbreviations**

- 51    53BP1 (P53-Binding Protein 1)
- 52    Acetylation (Ac)
- 53    ALC1 (Amplified in Liver Cancer 1)
- 54    Ataxia Telangiectasia Mutated (ATM)
- 55    Base excision repair (BER)
- 56    Casein kinase II (CK2)
- 57    C-terminal domain (CTD)
- 58    DNA methyltransferase (DNMT)
- 59    DNA-damage response (DDR)
- 60    DNA-dependent protein kinase (DNA-PK),
- 61    Dose Reduction Factor (DRF)
- 62    Double-strand breaks (DSBs)
- 63    FAT binding domain (FATC)
- 64    FKBP12-rapamycin-associated protein (FAT)
- 65    Heterochromatin protein 1 $\beta$  (HP1 $\beta$ )
- 66    Histone acetyltransferase (HAT)
- 67    Histone deacetylase (HDAC)
- 68    Homologous recombination (HR),
- 69    Hypoxia inducible factor (HIF-1)
- 70    Interferon Regulatory Factor-3 (IRF-3)
- 71    Ionizing radiation (IR)
- 72    Leucine Rich Region (LRR)
- 73    ligase IV (Lig4)
- 74    Matrix metalloproteinase (MMPs)
- 75    Microhomology-mediated end joining (MMEJ)
- 76    Non-homologous end joining (NHEJ)
- 77    Non-small cell lung cancers (NSCLC)

78 Nuclear localization signal (NLS)  
79 Nucleotide Excision Repair (NER)  
80 Phosphatidyl inositol-3 kinase (PI3K)  
81 Poly-ADP ribose polymerase 1 (PARP1)  
82 Reactive oxygen species (ROS)  
83 Severe Combined Immunodeficiency (SCID)  
84 Suberoylanilide hydroxamic acid (SAHA)  
85 Transactivation/transformation-domain-associated protein (TRRAP)  
86 Transcription Coupled Repair (TCR)  
87 Trichostatin A (TSA)  
88 Ultraviolet radiations (UVR)  
89 X-ray cross complementation group 4 protein (XRCC4)  
90 XRCC4-like factor (XLF)

91

92

## 93 **1. Introduction**

94 DNA replication and cell division are biological processes inherent in all prokaryotic and  
95 eukaryotic cells. In metazoans, errors in DNA replication caused by endogenous and exogenous  
96 factors, are common and result in thousands of DNA lesions each day [1]. In addition, normal  
97 cellular metabolism generates metabolic intermediates and by-products such as reactive oxygen  
98 species (ROS) and reactive nitrogen compounds that can induce DNA breaks. For the cells, these  
99 processes often “collide” when DNA replication machinery encounters ROS-damaged DNA  
100 bases or single-strand DNA breaks, which can be converted to DNA double-strand breaks  
101 (DSBs) during replication fork collapse [2]. Cellular processes such as meiotic recombination [3]  
102 or cleavage of genes during immunoglobulin gene rearrangement can also give rise to DSBs [4].  
103 Exposure to environmental DNA damaging agents such as ultraviolet radiations (UVR) and other

chemical or genotoxic agents are also an important cause of DNA lesions, and DNA DSBs are perhaps the most lethal kind of damage that a cell could encounter. DNA DSBs when not repaired or managed properly threaten genomic stability and can result in the development of cancers [5–7]. Cells have developed an array of mechanisms to combat the threats posed by different kinds of DNA damage. These mechanisms collectively called the DNA-damage response (DDR), detects DNA lesions, signal their presence and promote their repair [8,9]. In this review, we will primarily focus on the DDR as it pertains to DNA DSB repair.

When DNA DSBs trigger the DDR, a series of cellular responses converge on a fundamental binary decision: a) the activation of cell cycle checkpoints to facilitate DNA repair or b) activation of apoptosis when the degree of DNA damage passes a threshold from which the cell cannot recover and/or for which loss of the cell can be tolerated by cell replacement [7]. The cells are equipped with three distinct DNA repair pathways to combat the DSBs: homologous recombination (HR), non-homologous end joining (NHEJ), or microhomology-mediated end joining (MMEJ; also referred to as Alternative-NHEJ or Alt-NHEJ) [10–12]. HR is an error-free process that uses sister chromatids as templates for DNA repair and is mediated by RAD51. This is the predominant repair pathway during development and in the S and G2 phases of the cell cycle, and has the longest sequence homology requirement [13]. As the name suggests, MMEJ requires only a 5-25 bp microhomologous sequence to align the broken strands before joining the ends, and although active throughout the cell cycle is most prominent during S/G2 [14]. The requirement for the small stretch of microhomology results in deletions and induces chromosomal abnormalities and rearrangements [15]. NHEJ is responsible for the repair of the majority of the DSBs in G1 and G<sub>0</sub> phase of the cell cycle. Unlike HR and MMEJ, NHEJ does not require any homologous sequence for DNA repair and is highly error prone [16]. The NHEJ

pathway is mediated by an enzyme complex called DNA-dependent protein kinase (DNA-PK) [17,18].

## **2. DNA-PK Structure and Function**

Identified as individual components during the early 1980's, DNA-PK is a nuclear serine/threonine kinase, consisting of a catalytic subunit called DNA-PKcs and a regulatory heterodimer Ku (Ku70/Ku80). The initially recognized roles for DNA-PKcs (originally termed p350) involved phosphorylation and transcriptional activation of SP-1, p53, and hsp90 [11,19]. The Ku subunits were known to bind double strand DNA, but their function remained unknown for many years. Isolation of these two factors together led to the discovery of DNA-PK holoenzyme and its function in DNA repair pathways [11,20]. With the nuclear polypeptides reaching up to 4127 amino acids, DNA-PKcs is the largest kinase subunit, which depends entirely on DNA binding for its activity [20,21]. Studies of the amino acid sequence of DNA-PKcs have identified DNA-PK to be a member of phosphatidylinositol-3 kinase (PI3K) like kinase (PIKKs), but other than protein kinase activity, no lipid kinase activity has been reported for DNA-PKcs [22,23]. The regulatory subunit of DNA-PK, called Ku, is a heterodimeric protein with two tightly associated subunits Ku70 and Ku80, which forms a ring like structure through which DNA can pass. The abundant expression of DNA-PK in the nucleus allows it to rapidly identify and bind to DNA DSBs and initiating its repair mechanisms [24].

Structurally, DNA-PKcs consists of a DNA binding domain, a Ku binding domain, a Leucine Rich Region (LRR), FKBP12-rapamycin-associated protein (FAT), Ataxia Telangiectasia Mutated (ATM), transactivation/transformation-domain-associated protein (TRRAP), C terminal of FAT binding domain (FATC) and two phosphorylation clusters; PQR

and ABCDE. Ku heterodimer consists of a conserved von Willebrand-like domain (vWA), DNA heterodimerization core domain, SAP domain, nuclear localization signal (NLS) and a widely conserved C-terminal domain (CTD). Ku subunits have a high affinity for DNA fragments (higher affinity for DSBs than for single strand breaks) and DNA-PKcs affinity to DNA increases to ~100 folds in the presence of Ku subunits. For efficient binding and subsequent activation of DNA-PKcs, an interaction between the C-terminal 12 residues of Ku80 with DNA-PKcs is necessary [24,25]. Once activated, DNA-PKcs initiates a series of phosphorylation/auto phosphorylation events that are required primarily for cell cycle checkpoint signaling and DNA repair [26]. However, studies have shown that DNA-PKcs can also phosphorylate peptide substrates that are not bound to the DNA, suggesting that the DNA itself can induce a conformational change in the DNA-PKcs to activate its phosphorylation activity [27,28].

### ***2.1. Role of DNA-PK in NHEJ DSB repair***

The core protein complexes of NHEJ are the Ku subunits (Ku70/Ku80), DNA-PKcs, DNA ligase IV (Lig4), its cofactor the X-ray cross complementation group 4 protein (XRCC4) and the nuclease Artemis [29]. The process of NHEJ starts with the recognition and binding of the broken DNA ends by the ring-shaped Ku70 and Ku80 subunits [30,31]. This recruits monomeric DNA-PKcs through its interactions with Ku and DNA on both sides. Together with the Ku subunits, DNA-PKcs form the heterodimer DNA-PK. Following this, the DNA-PKcs dimerizes and interacts across the DNA termini and forms a synaptic complex [32]. DNA-PKcs recruitment facilitates the translocation of the Ku heterodimer into the DNA duplex and allows DNA-PKcs to serve as a tether for broken DNA ends [33]. It is also proposed that DNA-PKcs protect the DNA from exonucleolytic degradation and aligns the broken ends of DNA. In this

regard, DNA-PKcs act as a scaffold protein and aids in the localization of repair proteins to the site of DNA damage. DNA binding activates the kinase activity of DNA-PKcs and phosphorylates and alters the activity of other proteins that mediate NHEJ, including Ku70, Ku80, Artemis, XRCC4, and Lig4 [30]. Ligation of DNA ends is mediated by Lig4 with XRCC4. An additional factor, Cernunnos/XRCC4-like factor (XLF), has also been identified as a binding partner of the Lig4-XRCC4 complex and is necessary for efficient ligation by NHEJ [34]. Activated DNA-PKcs also phosphorylates Ser139 on histone variant H2AX ( $\gamma$ -H2AX), which is a well-known marker for DNA DSBs that recruits repair factors to the damaged site and coordinates the signaling cascades required for efficient repair [35,36]. DNA-PK activation and its activity are modulated by the DNA to which it binds. The 5' end of the DNA activates the kinase while the 3' end anneals the DNA termini across the break [37]. Mutation studies of the Ku subunits and DNA-PKcs have shown that the Ku80/DNA-PKcs interactions are necessary for DNA-PK activity and are not specific to any structural region of the Ku80 C-terminus. Moreover, each structural region within the Ku80 C-terminus is necessary for the activation of the kinase activity. It was also observed that the structural features of the substrate like DNA length, DNA overhangs, orientation and sequence of the overhangs, influence Ku80/DNA-PKcs interaction and DNA-PK activation [38].

#### <Fig. 1.>

DNA-PK's kinase activity is requisite for its role in NHEJ [39]. Although a significant number of DNA-PK target proteins have been identified (including Ku70, Ku80, Artemis, XRCC4, XLF, H2AX and DNA Lig4), it is now considered that the phosphorylation of these by DNA-PK is not required for successful NHEJ [40–42]. A recent study has shown that DNA-PK mediated phosphorylation facilitates DNA polymerase  $\lambda$  (pol  $\lambda$ )-mediated gap filling DNA

synthesis during NHEJ [43]. The most important target site of DNA-PK phosphorylation is the catalytic subunit of DNA-PK itself [44–46]. DNA-PK autophosphorylation is essential for regulation of end processing, enzyme inactivation, and complex dissociation. The autophosphorylation of two clusters of residues, ABCDE (residues 2609-2647) and PQR (residues 2023-2056) regulates DNA end access for subsequent processing and ligation [47–49]. Mutational studies have shown that phosphorylation within ABCDE opens the ends for processing, while phosphorylation within the PQR cluster was shown to have an inhibitory effect on end processing [44,50]. These phosphorylation events point towards a mechanism by which DNA-PK protects the DNA ends and allows processing only when it is needed. DNA-PKcs autophosphorylation also results in the loss of kinase activity leading to the dissociation of DNA-PKcs from the Ku-DNA complex. Both the ABCDE and PQR regions seem to be necessary for DNA-PKcs dissociation [50].

Despite NHEJ being the prevalent mechanism of DNA repair in G1, NHEJ and HR are in direct competition in S/G2 of the cell cycle, as evidenced by continued expression of NHEJ factors throughout the cell cycle [51]. This suggests that a mechanism exists that facilitates HR even if DNA-PK is recruited to the DSB first. One suggestion is that NHEJ and HR may be regulated in part by autophosphorylation of DNA-PK. DNA-PKcs autophosphorylation at the T, J, and K (JK cluster, Thr946, and Ser1004), does not affect end processing, and protects certain DSBs from NHEJ and promotes HR [52]. However, what mediates the autophosphorylation at the JK cluster is not known. Both the abundance of DNA-PKcs/Ku throughout the cell cycle and the higher rate of Ku recruitment to DSB sites over RAD51 recruitment, may also explain in part how NHEJ is preferred over HR [53,54] and it has been suggested that NHEJ is the default pathway for DSB repair, and that HR may be triggered only when NHEJ fails [55]. However,

this is a highly over-simplified model of the complex mechanisms controlling DNA repair pathway choice. These mechanisms are reviewed in detail elsewhere [56,57] and include cell cycle control of HR via CDK activity and the Cullin ligases [58–62], topics that are beyond the scope of this review.

With regard to alternative pathways of end joining, Ku is known to repress MMEJ [63], and DNA-PK activity is required for this suppression [40,64]. In addition, the poly-ADP ribose polymerase 1 (PARP1) can directly compete with DNA-PK and the Ku heterodimer for DNA end-binding to promote MMEJ [65]. Although not discussed here in detail, DNA-PK can also play a role in none-DSB repair pathways including repair of single-strand breaks and base excision repair (BER) of oxidized DNA bases [66–69].

## ***2.2. Role of DNA-PK in telomere maintenance and immunity***

The functions of DNA-PK in the cells are not limited to DNA repair mechanism(s) but include telomere maintenance, transcriptional and translational regulation of innate immunity. [11,20,70,71]. DNA-PKcs plays a crucial role in the protection of the telomeres and telomere capping. Ample expression of DNA-PKcs and Ku subunits in the telomere region coincides with this notion. It has therefore been speculated that the presence of DNA-PKcs at the telomere serves to protect the chromosome ends from nuclease activity. In agreement with this, studies conducted in mice deficient in both telomerase and DNA-PKcs showed a significantly higher rate of telomere shortening in comparison to telomerase knockout mice suggesting that DNA-PKcs also prevent shortening of the telomeres and hence can play a critical role in aging [10,20,72]. Being a core component of the NHEJ pathway, DNA-PK plays a major role in the generation of B-cells and T-cells by V(D)J recombination, where the non-specificity of the

pathway results in the production of wide range of immunological cells. The process is essential for the normal immunological functions of the body, and any alterations could result in the Severe Combined Immunodeficiency (SCID) phenotype or other immune-deficient diseases. Recent studies have shown the involvement of DNA-PK in viral infection-mediated innate immunity, where DNA-PK acts as a nucleic acid sensor, binding to cytoplasmic DNA's and activating Interferon Regulatory Factor-3 (IRF-3)-mediated transcriptional activation of various cytokines and chemokines [70,71].

Because of the importance of DNA-PK in the development of immune cells, inactivating mutations to DNA-PKcs often present with a SCID or radiosensitive SCID (RS-SCID) phenotype. These phenotypes are augmented if there is a defect in additional components of the NHEJ pathway [73]. SCID mice with defective DNA-PKcs function showed defects in V(D)J recombination, developed thymic T-cell lymphoma and also showed telomere fusions or shorter telomeres, but were viable and lived beyond one year of age [10]. However, spontaneous DNA-PKc mutations in specific strains of horses and dogs did not survive more than a few months of age and died due to infections [74,75]. Even though SCID patients with a mutant DNA-PKc were not reported until recently, mutations in other components of NHEJ pathway have been reported and showed similar phenotypes as in the mice models. In 2009, van der Berg and colleagues identified the first human RS-SCID patient, with an L3062R missense mutation in the DNA-PKcs FAT domain. The mutation led to deficient Artemis activation and resulted in reduced B and T cells in peripheral blood, but did not affect the kinase activity or its auto phosphorylation. Mouse models with mutations in Ku subunits also result in overlapping phenotypes including RS-SCID, growth defects, etc., but no spontaneous mutations or cases have been reported for the same [75,76].

### 3. Differential expression of DNA-PK in normal and cancer cells

DNA-PK is widely expressed in all mammalian cells, with primates showing up to 50 fold more expression compared to other mammals [77]. Cultured human cells also express DNA-PK abundantly, and there exist conflicting reports on DNA-PK being differentially expressed in different human tissues [21,78]. A study led by Moll et.al. in various normal human tissues, reported a higher expression of DNA-PK in meiotic/actively dividing cells (neural cells and reproductive tissues), while epithelial cells from different tissues (colon, kidney, pancreas, endometrium, prostate, testis, brain, nerve ganglia and skin) showed a moderate expression profile. Some tissues, such as resting breast and liver, showed low or no expression at all [78]. However, a similar study by Sakata and group reported the expression of DNA-PKcs and Ku in the liver and resting breast tissues as well and attributed these differences to the different antibodies used and the number of samples tested [79]. The RNA expression of components of DNA-PKcs did not show any drastic difference between the tissues analyzed, other than the RNA expression of Ku subunits being 2-4 fold higher than that of DNA-PKcs [78]. Terminally differentiated cells do not replicate their DNA and therefore are less likely to undergo any damages due to replication. They still undergo transcription and need to maintain their genetic integrity. Interestingly, these cells contain other repairing pathways such as Nucleotide Excision Repair (NER), or Transcription Coupled Repair (TCR) and do not undergo NHEJ, in which DNA-PK is essential [80]. While the earlier belief was that DNA DSB repair is down regulated in certain differentiated cells, recent studies on differentiated adipocytes and astrocytes showed an up regulation of DNA DSB repair with an increased expression of DNA-PK components [81,82].

<Fig. 2.>

Genomic instability caused by DNA damage and exacerbated by defects in the DDR is a ubiquitous feature of cancer cells and the aberrant response to DNA damage is a major driver of cancer progression as well as a determinant of a tumor's response to therapy [1,83–85]. Differential expression of DNA-PK in clinical samples of tumors strongly implicates dysregulation of DNA-PK levels in cancer development. Elevated expression of DNA-PK is observed in esophageal cancers and colorectal cancers compared to the normal mucosal cells surrounding the tumor [86]. Clinicopathological studies have identified elevated expression of DNA-PKcs in colorectal cancers, which correlated with the clinical stage of the disease, lymphatic invasion, and distant metastasis, making it a potential biomarker for clinical assessment of pathogenesis and prognosis [87]. DNA-PKcs over expression is also observed in nasopharyngeal carcinoma and was associated with poor overall survival rate compared to patients with lower expression of DNA-PKcs. However, some studies have shown no significant correlation between DNA-PKcs expression and clinical outcome of nasopharyngeal carcinoma [88]. Another study reported a loss of DNA-PKcs expression in ~22% (63 out of 279) of gastric cancers [89]. Intra-tumoral heterogeneity complicates accurate quantifications of DNA-PK expression in cancer cells. However, these studies implicate a crucial role for DNA-PKcs in the cancers of the gastrointestinal system. Non-small cell lung cancers (NSCLC) also exhibit a significant up regulation of DNA-PK expression which is also correlated with the differentiation degree of the disease, but was not associated with metastasis [90,91]. In glioma patients, the median survival rate of patients with high DNA-PK level was longer than that of patients with low DNA-PKcs. Recently it was reported that DNA-PK is involved in melanoma tumor progression and metastasis by regulating tumor angiogenesis, migration, and invasion. Secretomic analysis revealed that DNA-PK regulates the secretion of several metastases

associated proteins involved in tumor microenvironment modification, further indicating its crucial pro-metastatic role [92].

#### <Table 1>

Interestingly, in lymphoblastic cell lines, in spite of a higher RNA expression, DNA-PKcs level is reduced compared to normal cells, indicating a post-transcriptional, proteasome-dependent regulation of DNA-PKcs [93]. Despite the elevated DNA-PK level observed in many tumors, the attenuated DNA-PK level has also been reported in several studies. In peripheral blood lymphocytes of cancer patients, there was an inverse correlation between the DNA-PK activity and disease progression [94]. Attenuated and reduced level of DNA-PK is also observed in certain breast, cervical and lung cancers [95]. Somatic mutation in DNA-PK is also closely associated with tumor pathogenesis. A mutation in the critical threonine residue (Thr2609) is essential for the catalytic activity of DNA-PK, as observed in breast and pancreatic cancers. Single nucleotide polymorphism analysis has identified a mutation in a non-coding intron (6721 G to T) of DNA-PK, to be associated with bladder cancer and hepatocellular carcinoma [96]. These findings suggest a complex and intricate regulation of DNA-PK during tumor progression and its dual role in DNA damage and pro-tumorigenic survival pathways.

#### **4. Epigenetic alternations and genomic instability**

DNA in eukaryotic cells is packaged into chromatin, which protects the DNA from damage but hides any occurring damage to DNA repair enzymes. To overcome this physical barrier, major alterations including post-translational histone modifications and ATP-dependent chromatin remodeling factors are required in order to facilitate the accessibility of the DNA lesions to repair proteins [97–99].

334 By the term ‘epigenetic alterations’ we refer to reversible and heritable changes in gene  
335 function which are not caused by modifications in the underlying DNA sequence. These involve  
336 DNA methylation and multiple types of histone modifications such as various  
337 acetylations/deacetylations, methylations, etc. Moreover, extensive studies on microRNAs  
338 (miRNAs) have revealed their ability to target many genes post-transcriptionally, thus having an  
339 impact on gene expression [100–102]. Although the implication of these alterations in a plethora  
340 of cellular processes (e.g. cell differentiation, gene expression, imprinting, X chromosome  
341 inactivation, etc.) is fundamental for maintaining normal function, there is accumulating  
342 evidence that these changes are also associated with the pathophysiology underlining various  
343 human diseases including cancer [103–105]. Several studies have demonstrated the interaction  
344 between DNA-PK and epigenetic alterations during DNA repair mechanisms [36,106]. DNA  
345 DSBs initiate the phosphorylation of histone H2AX protein at the conserved serine residue  
346 (Ser139) in C terminus to generate  $\gamma$ -H2AX. This phosphorylation event is important for stable  
347 association of repair factors at DNA damage sites and is essential for maintaining genomic  
348 stability [107,108]. Moreover, the phosphorylation of H2AX by DNA-PK is stimulated by  
349 histone acetyltransferase (HAT), which act mainly on the N-terminal tails of H3 and H4, by  
350 inducing conformational changes of nucleosomes [109]. Interestingly, it has been shown that  
351 DNA-PKcs contain a bromodomain (BRD)-like module which is able to bind to H2AX acetyl-  
352 lysine 5 (K5ac) as well as to promote the phosphorylation of H2AX at Ser139. Radioresistant  
353 tumor cells often show increased levels of DNA-PKcs activation while treatment with JQ1, a  
354 Kac antagonist to the bromodomain module, led to re-sensitizing the cells to radiation [110].  
355 Furthermore, DNA-PK may indirectly modulate the levels of  $\gamma$ -H2AX after genotoxic damage  
356 through activation of Akt that in turn inhibits GSK3 $\beta$ , as inhibition of GSK3 $\beta$  signaling appears

to inhibit the dephosphorylation of  $\gamma$ -H2AX to a similar extent as the chemical inhibition of PP2A [36]; a known  $\gamma$ -H2AX phosphatase [111].

DNA-PK is also implicated in the epigenetic regulation of DNA repair. For example, DNA-PK can affect the activity of HAT hGCN5 during DNA repair. A study by Barlev et al. [106] reported that DNA-PK represses the activity of the bromodomain (BrD)-containing protein hGCN5 at several levels. At the first level, Ku70/80 may sequester hGCN5 in non-functional complexes through binding to its BrD. Second, DNA-PKcs interacts with Ku and phosphorylates hGCN5, resulting in the inhibition of HAT activity. However, more studies are required to investigate the role of DNA-PK in modulating hGCN5 activity [106]. MOF is another HAT protein that specifically acetylates histone H4 at lysine 16 (H4K16ac) position. Depletion of MOF resulted in a reduced level of H4K16ac, which correlates with the defective DDR process. This results in delayed accumulation of DNA-PK post-irradiation and decreases the association of MOF with DNA by preventing chromatin alterations that are essential for efficient DNA repair [99]. Tip60 is a HAT protein that has a crucial role in activation of DNA-PKcs kinase activity. This has been proved through silencing Tip60 expression blocking the autophosphorylation of DNA-PKcs. Furthermore, the association of DNA-PKcs with HAT increases its activity by 5-fold in response to bleomycin treatment [112]. ATP-dependent chromatin remodeling factors are another type of alterations that affect the function of DNA-PK. One study showed that the chromatin remodeling factor, Amplified in Liver Cancer 1 (ALC1) binds to DNA-PK and catalyzes nucleosome sliding through its interaction with poly (ADP-ribose) protein [113]. In addition, SIRT6, another chromatin regulatory factor, was found to play a critical role in the global deacetylation of Histone H3 Lysine 9 and is capable of stabilizing DNA-PKcs to chromatin at DNA DSB sites [114].

**<Fig. 3.>**

Histone methylation is another abundant post-translational modification that is implicated in the DDR process. The indirect interplay between DNA-PK and histone methylation in response to DNA damage was demonstrated by Jiang et al. [115]. DNA-PK phosphorylates a metabolic enzyme fumarase, at Thr236 following ionizing radiation. The phospho-fumarase interacts with H2A.Z, a H2A variant, at DSB regions and result in generation of fumarate which inhibits KDM2B histone demethylase activity that are responsible for H3K9me3 demethylation. This inhibition promotes the accumulation of DNA-PK at DSB for NHEJ-DNA repair by enhancing demethylation of H3 at Lys 36 position. However, Young et al. showed that DNA-PK is not required for the recruitment of KDM4B to sites of DNA damage induced by laser micro-irradiation [116]. The decrease in the level of H3K9 methylation is important for DNA repair by inducing chromatin relaxation [117]. Furthermore, a recent study showed that inhibition of DNA-PK resulted in elevated histone methyltransferase activity of EZH2 thereby suggesting that its phosphorylation by DNA-PK causes decreased EZH2 methyltransferase activity [118]. Moreover, in another report, heterochromatin protein 1 $\beta$  (HP1 $\beta$ ) was shown to interact with DNA-PKcs with the resulting binding being dependent on the methylation status of three specific lysine residues namely Lys1150, Lys2746 and Lys3248. Finally, replacement of lysine with arginine caused the improper function of DNA-PKcs, in the DDR, and consequently led to hypersensitivity to radiation [119]. DNA-PK was also found to be involved in histone ubiquitination of H2AX and H2A that are essential for further recruitment of repair proteins such as ATM, 53BP1 and BRCA1. DNA-PK has shown to promote H2AX and H2A monoubiquitination in response to DSBs induced by camptothecin, which causes transcription-blocking Top1cc, in WI38 fibroblast cells [120].

Another epigenetic marker which affects chromatin structure and genome stability is methylation of cytosine residues by DNA methyltransferase (DNMT). Despite of the interplay between DNA-PK and different histone modifications, the interaction between DNA-PK and DNA methylation is still not well understood. Indeed, DNMT1 was found to be involved in modulating DDR in DNA-methylation-independent manner by its recruitment to DSBs [121]. Ha et al. reported that DNA-PK is not involved in the recruitment of DNMT1 and it was primarily dependent on its interaction with ATR effector kinase CHK1 [122]. Furthermore, another group has shown that glioblastoma and lung carcinoma cells treated with DNMT inhibitors were more sensitive to radiation due to impairment of DDR [123]. In particular, DNA-PK-deficient glioblastoma cells were preferentially more sensitive to Zebularine (a DNMTs inhibitor) thus implying its potential interaction with epigenetic mechanisms [124].

Apart from DNA methylation and histone modifications, miRNAs have also been considered to act epigenetically to regulate gene expression. miRNAs are small, single-stranded RNAs which are firstly transcribed into their primary form (pri-miRNA), then are processed into a precursor form in the nucleus (pre-miRNA) and finally are exported to the cytoplasm where they are processed by the RNase III endonuclease Dicer into mature miRNAs [125,126]. There is evidence that a single miRNA may have more than hundred mRNA targets while an individual mRNA may be targeted by multiple miRNAs [127]. Findings from a recent report demonstrated that miR-488-3p was capable of sensitizing malignant melanoma cells to cisplatin treatment by targeting transcripts synthesized from *PRKDC* (the gene encoding DNA-PKcs) thus leading to a decline in its protein expression levels [128]. In addition, miR-21 was shown to provoke an increase in the activity of DNA-PKcs by targeting GSK3B, thus stimulating an increase in DSBs repair leading to radioresistance observed in various tumor cell lines [129]. Furthermore,

overexpression of miR-101 in lung and brain cancer cell lines was found to reduce the protein levels of DNA-PKcs, while increasing their sensitivity to radiation [130]. In another study, miR-101 sensitized pancreatic tumor cells to the effect(s) of gemcitabine while it also promoted apoptosis by down-regulating DNA-PKcs [131]. Reduced protein levels of DNA-PK were also observed in lung cancer cell lines following transfection with miR-101, hence causing radiosensitization [132]. Furthermore, miR-136 overexpression was associated with a decrease in the expression levels of DNA-PK in ovarian tumor cells [133]. On contrast, overexpression of miR-1323 was found to increase the protein levels of DNA-PKcs in primary lung cell lines, whereas silencing of miR-1323 in radioresistant lung tumor cells was followed by a decline in the protein content of DNA-PK [134].

Histone deacetylase (HDAC) inhibitors have been recorded as novel anticancer drugs and were found to cause an accumulation of DNA damage by suppressing the expression of DNA repair genes including DNA-PKcs [135]. Suberoylanilide hydroxamic acid (SAHA), a HDAC class I and II inhibitor, has been reported to downregulate the expression DNA-PK in human prostate carcinoma and glioma cells [136]. The treatment with Trichostatin A (TSA) radiosensitizes NSCLC cells by decreasing the expression level of Ku70, Ku80, and DNA-PKcs, leading to the inhibition of DNA repair capability [137]. Moreover, HAT inhibitors have been reported to sensitize the cancer cells towards radiotherapy and chemotherapy [138]. CBP and P200 are HAT proteins that were recruited to DSBs and cause acetylation of specific lysine within histone H3 and H4. The inhibition of CBP and P200 in lung cancer cells using inhibitors or small interfering RNA lead to the suppression of NHEJ by preventing the histone acetylation at damage sites and thereby suppressing the recruitment of Ku70 and Ku80 to DSBs [139]. These examples further indicated the role of epigenetic alterations in the function and regulation of

DNA-PK during DNA repair mechanism and the effect of DNA-PK on the proteins that are involved in these regulations.

## **5. Aberrant expression of DNA-PK**

Altered expression of DNA-PK contributes to cancer development, progression and metastasis by regulating a plethora of canonical pro-survival signaling pathways. Apart from the critical role of DNA-PK in DDR, it can transcriptionally regulate specific pro-tumorigenic pathways including genomic stability, hypoxia, metabolism and inflammatory responses. DNA-PK regulate the transcription of several genes (c-Myc, c-Jun, and p53) promoting tumor cell survival and proliferation. One study reported the interaction of DNA-PKcs with Akt which induces autophosphorylation of DNA-PKcs and promotes its kinase activity and recruitment at broken DNA ends [140]. Positive regulation by survival factors may affect the genomic rearrangement as it is reported that increased survival may alter the genomic stability [141]. DNA-PKcs was also shown to be regulated by casein kinase II (CK2), a kinase associated with enhanced cell cycle progression. Inhibition of CK2 in human glioblastoma cell lines (M059K and T98G) shown decreased phosphorylation of Akt kinases that were earlier reported to associate with DNA-PKcs [142]. Recently, DNA-PKcs has been shown to interact with the transcription factor SNAI1 (also referred to as snail), in response to DNA damage and promote cancer cell migration. The snail is a zinc finger protein belonging to the family of transcription factors that repress E-cadherin and thereby regulates epithelial to mesenchymal transition. DNA-PKcs activated by ionizing radiation (IR) was shown to phosphorylate Snail at Ser100 residue leading to Snail stabilization [143]. Phosphorylation of Snail at this residue negatively regulates DNA-PKcs kinase activity leading to inhibition of DNA damage repair resulting in genomic

472 rearrangement and instability. Snail overexpression also contributes to survival after DNA  
473 damage, a phenomenon not seen in cells lacking DNA-PK [144]. Findings from a recent report  
474 also outlined the role of DNA-PKcs as a transcriptional modulator by stimulating tumor  
475 progression and metastasis in prostate carcinoma [145]. Furthermore, DNA-PK is activated by  
476 mild hypoxic conditions by auto phosphorylation at Ser 2056 by a mechanism independent of  
477 DNA repair pathway and positively regulates hypoxia inducible factor (HIF-1) thereby activating  
478 several pro-tumorigenic genes [146]. RPA70, another protein involved in hypoxic response and  
479 DNA repair in cancer cells is also indirectly regulated by DNA-PK. The interaction between  
480 RPA70 and TP53 under normal conditions is disrupted by hypoxia induced DNA-PK by  
481 phosphorylating TP53, resulting in the release of RPA70, which mediates apoptotic resistance in  
482 cancer [147–149]. The interaction between DNA-PK and TP53 following cellular stress is  
483 complicated with conflicting results generated from in-vitro and in vivo studies [150].

484         DNA-PK specifically activates TP53 by phosphorylation. However, how this regulates  
485 TP53-mediated signaling that links to DNA damage response and cell cycle arrest/apoptosis,  
486 needs further in depth analysis [1,148]. p21<sup>WAF1/CIP1</sup> also known as cyclin dependent kinase  
487 inhibitor 1 or CDK-interacting protein 1, is a key target gene in p53-mediated cell fate after  
488 DNA damage. Following DNA damage, DNA-PKcs is recruited to the p21 promoter where it  
489 forms a complex with p53 protein leading to cell death. Inhibition of DNA-PKcs with its  
490 pharmacological inhibitor, NU-7026 blocked its interaction with p53 and restored p21  
491 transcription equivalent to undamaged levels and significantly reduced cell death following the  
492 pro-death stimulation. No such effects were observed on inhibiting ATM or ATM and Rad3-  
493 related (ATR) proteins, the other members of the PI3KK family, suggesting that DNA-PKcs  
494 negatively regulates p21 gene expression by modulating p53 binding at CDKN1A promoter.

It has been shown that reduced expression of DNA-PKcs correlates with in-efficient DNA damage induced repair response and increased radiosensitivity in mice [151]. Conversely, residual tumor cells in cervical cancers, which were resistant to radiation treatment, had a higher expression of DNA-PKcs showing a positive correlation between radioresistance and elevated DNA-PK level [152]. Down regulation of DNA-PKcs has also been found to positively correlated with chemosensitization in human cervical carcinoma and a radiosensitive phenotype in lymphoblastic cell lines [93,153]. Similarly, prostate cancer patients with elevated expression of DNA-PKcs in tumors, respond less to standard radiation therapy [154]. DNA-PK is also implicated in cetuximab (EGFR specific antibody) induced radiosensitization in lung and breast cancer cell lines, by immobilizing the complex of EGFR- DNA-PK in the cytoplasm and blocking EGFR transport into the nucleus [155]. A recent study, however, showed that patients with high levels of CD44 and DNA-PK had better overall survival rate and sensitized mesenchymal subtypes of glioblastoma to radiotherapy and temozolomide [156].

Differential secretomic studies have revealed that DNA-PKcs is directly involved in regulating tumor microenvironment by controlling the secretion of several proteins involved in tumor microenvironment modulation, like matrix metalloproteinase (MMPs) and gene products of at least 44 metastasis-associated genes. In tumors where DNA-PK was inhibited, there was a delay in tumor proliferation, mainly due to inhibition of MMPs. Furthermore, DNA-PK is also involved in regulating neo-angiogenesis in primary tumors. A low level of DNA-PK is associated with a delay in angiogenesis initiation, with a reduced potential to proliferate and metastasize [92]. Pre-clinical studies with dual inhibition of mammalian target of rapamycin (mTOR) kinase and DNA-PK has been shown to induce cytotoxicity and blocks cell survival pathways in chronic lymphocytic leukemia [157,158]. Although DNA-PKcs primary function

may be to signal and repair DNA DSBs incurred due to different stress or physiological parameters, its association with different transcription factors or other signaling molecules involved in cell death or cell survival, contributes to its role in safeguarding the genome.

## **6. Chemical and biological inhibitors of DNA-PK**

The most successful approach to inhibit DNA-PK is by small molecules that target the ATP-binding site of the kinase domain. Various investigations have revealed that a specific group of compounds (**Fig. 4**) can inhibit DNA-PK activity effectively [159,160]. The first identified inhibitor, wortmannin, obtained from the fungus *Penicillium funiculosum*, is a general competitive inhibitor of PI-3 kinase with an IC<sub>50</sub> value of 16 nM [161]. Wortmannin exhibits its inhibitory nature by irreversible alkylation of Lysine 802 residue at the active site of DNA-PKc's that is essential for phosphate transfer reaction. Wortmannin was identified as an effective radiosensitizer in a variety of normal and cancer cells with a Dose Reduction Factor (DRF) for IR at 10% survival (between 1.4 and 3). Being a DNA-PK inhibitor, wortmannin plays a significant role in inhibiting p53 phosphorylation and acetylation. Lin et al. have shown that p53 phosphorylation induced by benzo[a]pyrene on HepG2 cells suppress and accumulates p53 acetylation, which was moderately affected when treated with 20  $\mu$ M wortmannin [162]. Moreover, wortmannin has a vital role in the inhibition of histone modification. In ACC-LC-91 lung cancer cells, the histone H3 acetylation and histone H3K4 methylation induced by HDAC1 was found to be inhibited and regulated by wortmannin [163]. Further, the treatment in MCF7 cells with this inhibitor proves to be effective in preventing the formation of phosphorylated histones following DNA damage [164]. Despite all these interesting features, lack of specificity, poor solubility and non-specific toxicity has limit its clinical applications [10].

**<Fig. 4.>**

LY294002, a morpholine derivative of natural flavonoid quercetin, is another competitive DNA-PK inhibitor that binds irreversibly to the kinase domain of DNA-PK with an IC<sub>50</sub> value of 1.4  $\mu$ M producing a DRF at 10% survival with IR of 1.5 to 1.8. Even though LY204002 has generated interesting *in vivo* results as a radiosensitizing agent, rapid metabolic clearance, high *in vivo* toxicity, lack of specificity and poor stability prohibits its clinical use in humans [10,165]. However, LY294002 has been proved as a productive lead molecule for a series of compounds with favorable properties. Those compounds which are synthesized using LY294002 as a lead compound have improved specificity with regards to DNA-PK inhibition. Among these, NU7026 is considered as one of the most potent and selective small molecules with 70-fold more selectivity towards DNA-PK, compared to other PI-3Ks. NU7026 exhibited an inhibition of various targets with an IC<sub>50</sub> value of 0.23  $\mu$ M against DNA-PK, 13  $\mu$ M against PI3Ks, and > 100  $\mu$ M for ATM or ATR. This compound enhanced the cytotoxicity of other chemotherapeutic drugs like idarubicin, daunorubicin, doxorubicin, etoposide, and amsacrine [165]. Rapid absorption is possible due to the mono hydroxylation of the second position of the morpholino group, resulting in an opened ring structure. Wang et al. showed that it is efficient in blocking DNA-PK activation induced by cisplatin without bringing any alteration to histone H4 expression [166]. NU7441 is another molecule based on the LY294002 backbone with improved potency having an IC<sub>50</sub> value of 0.3  $\mu$ M for DNA-PK and 7.0  $\mu$ M for PI3K proteins [167,168].

Other structurally distinct compounds found to inhibit DNA-PK are OK1035 [168] and SU11752 [169]. Both compounds lack the required potency for further development studies. Vanillin is a phenolic aldehyde obtained from certain species of vanilla pods also inhibit DNA-PK activity [170]. The structural simplicity of vanillin makes it an attractive lead molecule for a

lead optimization campaign. Two methoxybenzaldehyde derivatives of vanillin, 2-nitro and 3-iodo, were found to have improved DNA-PK inhibitory properties than vanillin [171,172]. This may be due to the electron withdrawing nature of  $-\text{NO}_2$  which increases the reactivity of aldehyde group towards the amino group of the protein, and this mechanism was not observed in 3-iodo substituted compounds [169]. Anti-cancer agent NK314 [98], is an inhibitor of both topoisomerase II $\alpha$  and DNA-PK. Other compounds found to have inhibitory property against DNA-PK are PI103, PP121, KU-0060648, and CC-115 [98,157,171,173,174]. Among these, PI103 is a potent ATP-competitive DNA-PK inhibitor. PP121 inhibits DNA-PK with an IC<sub>50</sub> value of 60 nM, while KU-0060648 is a dual inhibitor of DNA-PK, PI3K $\alpha$ , PI3K $\beta$  and PI3K $\delta$  with an IC<sub>50</sub> value of 8.6 nM, 4 nM, 0.5 nM and 0.1 nM, respectively. The differences in selectivity of these compounds are due to the structural differences and similarity that exists within the active site of DNA-PK [174]. While many small molecule inhibitors have been developed to target DNA-PK, there is a need to screen for new classes of compounds that can selectively inhibit DNA-PK's activity and/or expression in cancerous cells to improve cancer treatments with therapeutic agents that induce DNA DSBs, such as radiotherapy.

The majority of research so far has been carried out using small organic/synthetic compounds as DNA-PK inhibitors. A shift in focus to nucleotide and antibody based inhibitors have shown higher efficacy in DNA-PK inhibition. The two primary obstacles faced by small organic compounds, such as poor solubility and/or short serum half-lives, would need to be overcome to facilitate clinical utilization [175]. One such nucleotide is GRN163L, a 13-mer oligonucleotide which inhibits the phosphorylation of DNA-PK and increases  $\gamma$ -H2AX phosphorylation in chronic lymphocytic leukemia (CLL) lymphocytes in response to treatment with fludarabine, a nucleotide analog [176]. A similar effect has been reported by an antibody

based inhibitor, Folate-ScFv 18-2, where it caused radiosensitization in human KB oral carcinoma and NCI-H292 lung cancer cells [177]. Further, a study by Kim et al. in the breast cancer cell lines NCI and MDA-MB-231 has shown how peptides can be effective in DNA-PK inhibition. A targeting peptide (HNI-38) containing c-terminus of Ku-80, inhibited the activity of DNA-PK up to 50% by interfering with the interaction between DNA-PKcs and Ku complex thereby lowering the resistance of the cells to IR [178].

The strategy of using small interfering RNA (siRNA) oligonucleotide is an alternative strategy to suppress DNA-PK activity in cells. A study by An et al., showed that knocking down DNA-PK expression with siRNAs targeting the DNA-PKcs catalytic motif resulted in increased radiosensitization in HeLa cells. It was demonstrated that DNA-PK silencing by siRNA could also lead to the downregulation of the activity and expression of the c-myc protein [179] which is a driving oncogene essential for the progression of the cell cycle [180]. The knockdown of DNA-PKcs using siRNA in low passage human fibroblasts showed that radiation-induced interphase chromosome breaks were repaired at a reduced rate and there was an increase in the yield of acentric chromosome fragments in addition to an increased radiosensitivity [181]. Research by Collis et al. using prostate cancer cell lines DU145 and PC3, showed that transient transfection with plasmids encoding DNAS-PK-targeting siRNA, rendered them hyper-sensitive to IR [182].

In addition to siRNA approaches, antisense oligonucleotides (2'-O-methoxyethyl/uniform phosphorothioate chimeric antisense oligonucleotides or ASOs) can also be used to specifically target DNA-PK expression. Using DNA-PK-targeting antisense oligonucleotides caused an increase in cell death in human glioma cell lines (M059K) after treatment with ionizing radiation, bleomycin, and etoposide [183]. In addition to sensitize the cells to IR, ASOs can also induce autophagy. Human malignant glioma M059K, U373-MG, and T98G cells treated with

ASOs targeting DNA-PK, were sensitized to low doses or IR by inducing autophagy [184]. Introduction of ASOs targeting Ku70 to human lung squamous cell carcinoma resulted in an increased sensitivity to cytotoxic agents such as bleomycin, methyl methanesulfonate and to IR. This study achieved a partial reduction of DNA end binding activity by KU by partially reducing Ku 70 protein expression [185]. Taken together, DNA-PK is an important cancer therapeutic target that can be inhibited both functionally by small molecule inhibitors, peptides and antibodies as well as by suppressing its expression via siRNA and ASO approaches.

## **7. Conclusions and future directions**

Conventional cancer therapy including radiotherapy and chemotherapy depends on inducing DNA lesions, some of which are repaired by DNA-PK-dependent pathways. Therefore, the function and expression of DNA-PK has a significant impact on therapy outcome in different ways. First, DNA-PK expression can be utilized as a biomarker for predicting prognosis and response to cancer treatments. However, the heterogeneity of DNA-PK expression in different types of tumors and within the same tumor makes it difficult to employ DNA-PK as a biomarker in clinical settings. In addition, the DNA-PK function is pleiotropic, and loss or gain of DNA-PK may impact both cell signaling pathways (e.g., Akt/G3Kb) and gene transcription via both direct interaction with transcription factors and via epigenetic mechanisms. Thus, how DNA-PK expression regulates tumor response to radiotherapy and chemotherapy is likely complex and will require further study to allow this kinase to be effectively used as a biomarker for treatment response. Second, chemicals and biologicals that target DNA-PK may greatly improve the outcome of cancer therapy. To fully realize the clinical utility of DNA-PK targeting in cancer therapy, further refinement and development of approaches targeting the function and/or expression of DNA-PK are of critical importance. Future studies should, therefore, aim at the

633 development of more specific inhibitors and on finding ways to ensure the differential inhibition  
634 of DNA-PK using a broad range of cancer cells. In the new era of research, epigenetics may well  
635 address these challenges.

636

#### 637 **Conflict of interest**

638 There is no conflict of interest to declare on this review article.

639

#### 640 **Acknowledgement**

641 Work in HPVR laboratory is funded by Natural Sciences and Engineering Research Council  
642 (NSERC) (RGPIN 246127). GD is a Senior Scientist at the Beatrice Hunter Cancer Research  
643 Institute (BHCRI) and his laboratory's work on DNA repair is funded by a Discovery Grant from  
644 the NSERC (RGPIN 05616).

## References

- [1] S.P. Jackson, J. damage can result from diverse causes Bartek, The DNA-damage response in human biology and disease., *Nature*. 461 (2009) 1071–1078. doi:10.1038/nature08467.
- [2] W.J. Cannan, D.S. Pederson, Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin, *J. Cell. Physiol.* 231 (2016) 3–14. doi:10.1002/jcp.25048.
- [3] C.L. Sansam, R.J. Pezza, Connecting by breaking and repairing: mechanisms of DNA strand exchange in meiotic recombination, *FEBS J.* 282 (2015) 2444–2457. doi:10.1111/febs.13317.
- [4] F.W. Alt, Y. Zhang, F.L. Meng, C. Guo, B. Schwer, Mechanisms of programmed DNA lesions and genomic instability in the immune system, *Cell*. 152 (2013) 417–429. doi:10.1016/j.cell.2013.01.007.
- [5] J.D. Watson, T. a. Baker, S.P. Bell, A. Gann, M. Levine, R. Losick, *Molecular biology of the gene*, Pearson Educ. Inc. (2003). doi:10.1007/SpringerReference\_167621.
- [6] M.C. Negritto, Repairing double-strand DNA breaks, *Nat. Educ.* (2010). doi:10.1038/nsmb.1710.
- [7] E.R. Phillips, P.J. McKinnon, DNA double-strand break repair and development., *Oncogene*. 26 (2007) 7799–7808. doi:10.1038/sj.onc.1210877.
- [8] G. Raschellà, G. Melino, M. Malewicz, New factors in mammalian DNA repair—the chromatin connection, *Oncogene*. (2017). doi:10.1038/onc.2017.60.
- [9] A. Georgoulis, C.E. Vorgias, G.P. Chrousos, E.P. Rogakou, Genome instability and  $\gamma$ H2AX, *Int. J. Mol. Sci.* 18 (2017). doi:10.3390/ijms18091979.
- [10] S.J. Collis, T.L. DeWeese, P.A. Jeggo, A.R. Parker, The life and death of DNA-PK, *Oncogene*. 24 (2005) 949–961. doi:10.1038/sj.onc.1208332.
- [11] R. Hill, P.W.K. Lee, The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet?, *Cell Cycle*. 9 (2010) 3460–9. doi:10.4161/cc.9.17.13043.
- [12] J. Dahm-Daphi, P. Hubbe, F. Horvath, R.A. El-Awady, K.E. Bouffard, S.N. Powell, H. Willers, Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53, *Oncogene*. 24 (2005) 1663–1672. doi:10.1038/sj.onc.1208396.
- [13] L.E.M. Vriend, P.M. Krawczyk, Nick-initiated homologous recombination: Protecting the genome, one strand at a time, *DNA Repair (Amst)*. 50 (2017) 1–13. doi:10.1016/j.dnarep.2016.12.005.
- [14] L.N. Truong, Y. Li, L.Z. Shi, P.Y.-H. Hwang, J. He, H. Wang, N. Razavian, M.W. Berns, X. Wu, Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells., *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 7720–5. doi:10.1073/pnas.1213431110.
- [15] M. McVey, S.E. Lee, MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings, *Trends Genet.* (2008). doi:10.1016/j.tig.2008.08.007.
- [16] J.K. Moore, J.E. Haber, Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in *Saccharomyces cerevisiae*, *Mol Cell Biol.* (1996). doi:10.1128/MCB.16.5.2164.
- [17] G.C.M. Smith, S.P. Jackson, The DNA-dependent protein kinase, *Genes Dev.* 13 (1999) 916–934.
- [18] M.R. Lieber, The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway., *Annu. Rev. Biochem.* (2010).

- doi:10.1146/annurev.biochem.052308.093131.
- [19] U. Yavuzer, G.C.M. Smith, T. Bliss, D. Werner, S.P. Jackson, DNA end-independent activation of DNA-PK mediated via association with the DNA-binding protein C1D, *Genes Dev.* 12 (1998) 2188–2199. doi:10.1101/gad.12.14.2188.
  - [20] N. Jette, S.P. Lees-Miller, The DNA-dependent protein kinase: a multifunctional protein kinase with roles in DNA double strand break repair and mitosis, *Prog Biophys Mol Biol.* 117 (2015) 1–29. doi:10.1016/j.pbiomolbio.2014.12.003.
  - [21] J.A. Neal, K. Meek, Choosing the right path: Does DNA-PK help make the decision?, *Mutat. Res. - Fundam. Mol. Mech. Mutagen.* 711 (2011) 73–86. doi:10.1016/j.mrfmmm.2011.02.010.
  - [22] K.O. Hadley, D. Gell, G.C.M. Smith, H. Zhang, N. Divecha, M.A. Connelly, A. Admon, S.P. Lees-Miller, C.W. Anderson, S.P. Jackson, DNA-Dependent Protein Kinase Catalytic Subunit: A Relative of Phosphatidylinositol 3-Kinase and the Ataxia Telangiectasia Gene Product, *Cell.* 82 (1995) 849–856. doi:10.1016/0092-8674(95)90482-4.
  - [23] G.C. Smith, N. Divecha, N.D. Lakin, S.P. Jackson, DNA-dependent protein kinase and related proteins., *Biochem. Soc. Symp.* (1999).
  - [24] G.J. Grundy, H.A. Moulding, K.W. Caldecott, S.L. Rulten, One ring to bring them all-The role of Ku in mammalian non-homologous end joining, *DNA Repair (Amst).* 17 (2014) 30–38. doi:10.1016/j.dnarep.2014.02.019.
  - [25] X. Kong, Y. Shen, N. Jiang, X. Fei, J. Mi, Emerging roles of DNA-PK besides DNA repair, *Cell. Signal.* 23 (2011) 1273–1280. doi:10.1016/j.cellsig.2011.04.005.
  - [26] V.C. George, G. Dellaire, H.P.V. Rupasinghe, Plant flavonoids in cancer chemoprevention: role in genome stability, *J. Nutr. Biochem.* 45 (2017) 1–14. doi:10.1016/j.jnutbio.2016.11.007.
  - [27] Q. Ding, Y.V.R. Reddy, W. Wang, T. Woods, P. Douglas, D.A. Ramsden, S.P. Lees-Miller, K. Meek, Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair, *Mol. Cell. Biol.* 23 (2003) 5836–5848. doi:10.1128/MCB.23.16.5836.
  - [28] X. Cui, Y. Yu, S. Gupta, Y.-M. Cho, S.P. Lees-Miller, K. Meek, Autophosphorylation of DNA-Dependent Protein Kinase Regulates DNA End Processing and May Also Alter Double-Strand Break Repair Pathway Choice, *Mol. Cell. Biol.* 25 (2005) 10842–10852. doi:10.1128/MCB.25.24.10842–10852.2005.
  - [29] C.A. Brosey, Z. Ahmed, S.P. Lees-Miller, J.A. Tainer, What Combined Measurements From Structures and Imaging Tell Us About DNA Damage Responses, in: *Methods Enzymol.*, 2017: pp. 417–455. doi:10.1016/bs.mie.2017.04.005.
  - [30] S.P. Lees-Miller, K. Meek, Repair of DNA double strand breaks by non-homologous end joining, *Biochimie.* (2003) 1161–1173. doi:10.1016/j.biochi.2003.10.011.
  - [31] J. Dahm-Daphi, P. Hubbe, F. Horvath, R.A. El-Awady, K.E. Bouffard, S.N. Powell, H. Willers, Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53, *Oncogene.* 24 (2005) 1663–1672. doi:10.1038/sj.onc.1208396.
  - [32] D. Woods, J.J. Turchi, Chemotherapy induced DNA damage response Convergence of drugs and pathways, *Cancer Biol. Ther.* 14 (2013) 379–389. doi:10.4161/cbt.23761.
  - [33] A. Rivera-Calzada, L. Spagnolo, L.H. Pearl, O. Llorca, Structural model of full-length human Ku70–Ku80 heterodimer and its recognition of DNA and DNA-PKcs, *EMBO Rep.* 8 (2006) 56–62. doi:10.1038/sj.embor.7400847.

- [34] P. Ahnesorg, P. Smith, S.P. Jackson, XLF interacts with the XRCC4-DNA Ligase IV complex to promote DNA nonhomologous end-joining, *Cell*. 124 (2006) 301–13. doi:10.1016/j.cell.2005.12.031.
- [35] A. Sak, M. Stuschke, Use of  $\gamma$ H2AX and other biomarkers of double-strand breaks during radiotherapy, *Semin. Radiat. Oncol.* (2010) 223–231. doi:10.1016/j.semradonc.2010.05.004.
- [36] J. An, Y.-C. Huang, Q.-Z. Xu, L.-J. Zhou, Z.-F. Shang, B. Huang, Y. Wang, X.-D. Liu, D.-C. Wu, P.-K. Zhou, DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression., *BMC Mol. Biol.* 11 (2010) 18. doi:10.1186/1471-2199-11-18.
- [37] K.S. Pawelczak, B.J. Andrews, J.J. Turchi, Differential activation of DNA-PK based on DNA strand orientation and sequence bias, *Nucleic Acids Res.* 33 (2005) 152–161. doi:10.1093/nar/gki157.
- [38] D.S. Woods, C.R. Sears, J.J. Turchi, Recognition of DNA termini by the cterminal region of the Ku80 and the dnadependent protein kinase catalytic subunit, *PLoS One*. 10 (2015) 1–19. doi:10.1371/journal.pone.0127321.
- [39] L.J. Kienker, E.K. Shin, K. Meek, Both V(D)J recombination and radioresistance require DNA-PK kinase activity, though minimal levels suffice for V(D)J recombination., *Nucleic Acids Res.* 28 (2000) 2752–61.
- [40] R. Perrault, H. Wang, M. Wang, B. Rosidi, G. Iliakis, Backup pathways of NHEJ are suppressed by DNA-PK, *J. Cell. Biochem.* 92 (2004) 781–794. doi:10.1002/jcb.20104.
- [41] Y. Yu, B.L. Mahaney, K.I. Yano, R. Ye, S. Fang, P. Douglas, D.J. Chen, S.P. Lees-Miller, DNA-PK and ATM phosphorylation sites in XLF/Cernunnos are not required for repair of DNA double strand breaks, *DNA Repair (Amst)*. 7 (2008) 1680–92. doi:10.1016/j.dnarep.2008.06.015.
- [42] A.A. Goodarzi, Y. Yu, E. Riballo, P. Douglas, S.A. Walker, R. Ye, C. Härer, C. Marchetti, N. Morrice, P.A. Jeggo, S.P. Lees-Miller, DNA-PK autophosphorylation facilitates Artemis endonuclease activity., *EMBO J.* 25 (2006) 3880–3889. doi:10.1038/sj.emboj.7601255.
- [43] G. Sastre-Moreno, J.M. Pryor, M. Moreno-Oñate, A.M. Herrero-Ruiz, F. Cortés-Ledesma, L. Blanco, D.A. Ramsden, J.F. Ruiz, Regulation of human pol $\lambda$  by ATM-mediated phosphorylation during non-homologous end joining, *DNA Repair (Amst)*. (2017) 1–15. doi:10.1016/j.dnarep.2017.01.004.
- [44] K. Meek, P. Douglas, X. Cui, Q. Ding, S.P. Lees-Miller, trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining., *Mol. Cell. Biol.* 27 (2007) 3881–90. doi:10.1128/MCB.02366-06.
- [45] D.W. Chan, B.P.-C. Chen, S. Prithivirajasingh, A. Kurimasa, M.D. Story, J. Qin, D.J. Chen, Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks, *Genes Dev.* 16 (2002) 2333–2338. doi:10.1101/gad.1015202.
- [46] Y. Zhou, J.H. Lee, W. Jiang, J.L. Crowe, S. Zha, T.T. Paull, Regulation of the DNA Damage Response by DNA-PKcs Inhibitory Phosphorylation of ATM, *Mol. Cell.* 65 (2017) 91–104. doi:10.1016/j.molcel.2016.11.004.
- [47] Q. Ding, Y.V.R. Reddy, W. Wang, T. Woods, P. Douglas, D.A. Ramsden, S.P. Lees-Miller, K. Meek, Autophosphorylation of the catalytic subunit of the DNA-dependent

- protein kinase is required for efficient end processing during DNA double-strand break repair, *Mol. Cell. Biol.* 23 (2003) 5836–48. doi:10.1128/MCB.23.16.5836.
- [48] S. Soubeyrand, L. Pope, B. Pakuts, R.J.G. Haché, Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation, *Cancer Res.* 63 (2003) 1198–201.
  - [49] P. Douglas, G.P. Sapkota, N. Morrice, Y. Yu, A.A. Goodarzi, D. Merkle, K. Meek, D.R. Alessi, S.P. Lees-Miller, Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase., *Biochem. J.* 368 (2002) 243–51. doi:10.1042/BJ20020973.
  - [50] P. Douglas, X. Cui, W.D. Block, Y. Yu, S. Gupta, Q. Ding, R. Ye, N. Morrice, S.P. Lees-Miller, K. Meek, The DNA-dependent protein kinase catalytic subunit is phosphorylated in vivo on threonine 3950, a highly conserved amino acid in the protein kinase domain., *Mol. Cell. Biol.* 27 (2007) 1581–91. doi:10.1128/MCB.01962-06.
  - [51] S.E. Lee, R.A. Mitchell, A. Cheng, E.A. Hendrickson, Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle, *Mol Cell Biol.* 17 (1997) 1425–33.
  - [52] J.A. Neal, V. Dang, P. Douglas, M.S. Wold, S.P. Lees-Miller, K. Meek, Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation., *Mol. Cell. Biol.* 31 (2011) 1719–33. doi:10.1128/MCB.01298-10.
  - [53] F. Chen, A. Nastasi, Z. Shen, M. Brenneman, H. Crissman, D.J. Chen, Cell cycle-dependent protein expression of mammalian homologs of yeast DNA double-strand break repair genes Rad51 and Rad52., *Mutat. Res.* 384 (1997) 205–11.
  - [54] Z. Mao, M. Bozzella, A. Seluanov, V. Gorbunova, Comparison of nonhomologous end joining and homologous recombination in human cells, *DNA Repair.* 7 (2008) 1765–1771. doi:S1568-7864(08)00247-4 [pii]\r10.1016/j.dnarep.2008.06.018.
  - [55] F. Delacôte, M. Han, T.D. Stamato, M. Jasin, B.S. Lopez, An xrc4 defect or Wortmannin stimulates homologous recombination specifically induced by double-strand breaks in mammalian cells., *Nucleic Acids Res.* 30 (2002) 3454–63. doi:10.1093/nar/gkf452.
  - [56] R. Ceccaldi, B. Rondinelli, A.D. D’Andrea, Repair Pathway Choices and Consequences at the Double-Strand Break, *Trends Cell Biol.* 26 (2016) 52–64. doi:10.1016/j.tcb.2015.07.009.
  - [57] K.K. Chiruvella, Z. Liang, T.E. Wilson, Repair of double-strand breaks by end joining., *Cold Spring Harb. Perspect. Biol.* 5 (2013). doi:10.1101/cshperspect.a012757.
  - [58] L.P. Ferretti, L. Lafranchi, A.A. Sartori, Controlling DNA-end resection: A new task for CDKs, *Front. Genet.* 4 (2013). doi:10.3389/fgene.2013.00099.
  - [59] J. Falck, J. V Forment, J. Coates, M. Mistrik, J. Lukas, J. Bartek, S.P. Jackson, CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination, *EMBO Rep.* 13 (2012) 561–568. doi:10.1038/embor.2012.58.
  - [60] L. Wohlbald, K.A. Merrick, S. De, R. Amat, J.H. Kim, S. Larochelle, J.J. Allen, C. Zhang, K.M. Shokat, J.H.J. Petrini, R.P. Fisher, Chemical Genetics Reveals a Specific Requirement for Cdk2 Activity in the DNA Damage Response and Identifies Nbs1 as a Cdk2 Substrate in Human Cells, *PLoS Genet.* 8 (2012). doi:10.1371/journal.pgen.1002935.
  - [61] N. Tomimatsu, B. Mukherjee, M. Catherine Hardebeck, M. Ilcheva, C. Vanessa Camacho, J. Louise Harris, M. Porteus, B. Llorente, K.K. Khanna, S. Burma, Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice., *Nat.*

- Commun. 5 (2014) 3561. doi:10.1038/ncomms4561.
- [62] A. Orthwein, S.M. Noordermeer, M.D. Wilson, S. Landry, R.I. Enchev, A. Sherker, M. Munro, J. Pinder, J. Salsman, G. Dellaire, B. Xia, M. Peter, D. Durocher, A mechanism for the suppression of homologous recombination in G1 cells, *Nature*. 528 (2015) 422–426. doi:10.1038/nature16142.
  - [63] F. Fattah, E.H.H. Lee, N. Weisensel, Y. Wang, N. Lichter, E.A. Hendrickson, Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells., *PLoS Genet*. 6 (2010) e1000855. doi:10.1371/journal.pgen.1000855.
  - [64] D. Udayakumar, C.L. Bladen, F.Z. Hudson, W.S. Dynan, Distinct Pathways of Nonhomologous End Joining that Are Differentially Regulated by DNA-dependent Protein Kinase-mediated Phosphorylation, *J. Biol. Chem*. 278 (2003) 41631–5. doi:10.1074/jbc.M306470200.
  - [65] M. Wang, W. Wu, W. Wu, B. Rosidi, L. Zhang, H. Wang, G. Iliakis, PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways, *Nucleic Acids Res*. 34 (2006) 6170–6182. doi:10.1093/nar/gkl840.
  - [66] Y.J. Choi, H. Li, M.Y. Son, X.H. Wang, J.L. Fornasaglio, R.W. Sobol, M. Lee, J. Vijg, S. Imholz, M.E.T. Doll?, H. Van Steeg, E. Reiling, P. Hasty, Deletion of individual Ku subunits in mice causes an NHEJ-independent phenotype potentially by altering apurinic/apyrimidinic site repair, *PLoS One*. 9 (2014). doi:10.1371/journal.pone.0086358.
  - [67] A.A. Kosova, O.I. Lavrik, S.N. Khodyreva, Role of Ku antigen in the repair of apurinic/apyrimidinic sites in DNA, *Mol. Biol*. 49 (2015) 67–74. doi:10.1134/S0026893315010070.
  - [68] P. Peddi, C.W. Loftin, J.S. Dickey, J.M. Hair, K.J. Burns, K. Aziz, D.C. Francisco, M.I. Panayiotidis, O.A. Sedelnikova, W.M. Bonner, T.A. Winters, A.G. Georgakilas, DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells, *Free Radic. Biol. Med*. 48 (2010) 1435–43. doi:10.1016/j.freeradbiomed.2010.02.033.
  - [69] N.S. Gavande, P.S. Vandervere-Carozza, H.D. Hinshaw, S.I. Jalal, C.R. Sears, K.S. Pawelczak, J.J. Turchi, DNA repair targeted therapy: The past or future of cancer treatment?, *Pharmacol. Ther*. 160 (2016) 65–83. doi:10.1016/j.pharmthera.2016.02.003.
  - [70] J.F. Goodwin, K.E. Knudsen, Beyond DNA repair: DNA-PK function in cancer, *Cancer Discov*. 4 (2014) 1126–1139. doi:10.1158/2159-8290.CD-14-0358.
  - [71] B.J. Ferguson, D.S. Mansur, N.E. Peters, H. Ren, G.L. Smith, DNA-PK is a DNA sensor for IRF-3-dependent innate immunity, *Elife*. 2012 (2012) 1–17. doi:10.7554/eLife.00047.
  - [72] E.S. Williams, R. Klingler, B. Ponnaiya, T. Hardt, E. Schrock, S.P. Lees-miller, K. Meek, R.L. Ullrich, S.M. Bailey, Telomere Dysfunction and DNA-PKcs Deficiency: characterization and consequence, *Cancer Res*. 69 (2009) 2100–2107. doi:10.1158/0008-5472.CAN-08-2854.Telomere.
  - [73] L. Woodbine, J.A. Neal, N.K. Sasi, M. Shimada, K. Deem, H. Coleman, W.B. Dobyns, T. Ogi, K. Meek, E.G. Davies, P.A. Jeggo, PRKDC mutations in a SCID patient with profound neurological abnormalities, *J. Clin. Invest*. 123 (2013) 2969–2980. doi:10.1172/JCI67349.
  - [74] L.E. Perryman, Molecular Pathology of Severe Combined Immunodeficiency in Mice, Horses, and Dogs, *Vet Pathol*. 100 (2004) 95–100.
  - [75] M. van der Burg, J.J.M. van Dongen, D.C. van Gent, DNA-PKcs deficiency in human:

- long predicted, finally found., *Curr. Opin. Allergy Clin. Immunol.* 9 (2009) 503–509. doi:10.1097/ACI.0b013e3283327e41.
- [76] M. Van Der Burg, H. Ijspeert, N.S. Verkaik, T. Turul, W.W. Wiegant, K. Morotomi-yano, P. Mari, I. Tezcan, D.J. Chen, M.Z. Zdzienicka, J.J.M. Van Dongen, D.C. Van Gent, A DNA-PKcs mutation in a radiosensitive T-B-SCID patient inhibits Artemis activation and nonhomologous end-joining, *J. Clin. Invest.* 119 (2009) 91–98. doi:10.1172/JCI37141DS1.
- [77] N.J. Finnie, T.M. Gottlieb, T. Blunt, P. a Jeggo, S.P. Jackson, DNA-dependent protein kinase activity is absent in xrs-6 cells: implications for site-specific recombination and DNA double-strand break repair., *Proc. Natl. Acad. Sci. U. S. A.* 92 (1995) 320–324.
- [78] U. Moll, R. Lau, M.A. Sypes, M.M. Gupta, C.W. Anderson, DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues, *Oncogene.* 18 (1999) 3114–3126.
- [79] K.-I. Sakata, Y. Matsumoto, H. Tauchi, M. Satoh, A. Oouchi, H. Nagakura, K. Koito, Y. Hosoi, N. Suzuki, K. Komatsu, M. Hareyama, EXPRESSION OF GENES INVOLVED IN REPAIR OF DNA DOUBLE-STRAND BREAKS IN NORMAL AND TUMOR TISSUES, *Int. J. Radiat. Oncology, Biol.* 49 (2001) 161–167.
- [80] T. Nospikel, DNA repair in differentiated cells: Some new answers to old questions, *Neuroscience.* 145 (2007) 1213–1221. doi:10.1016/j.neuroscience.2006.07.006.
- [81] A. Meulle, B. Salles, D. Daviaud, P. Valet, C. Muller, Positive regulation of DNA double strand break repair activity during differentiation of long life span cells: The example of adipogenesis, *PLoS One.* 3 (2008). doi:10.1371/journal.pone.0003345.
- [82] P. Fortini, E. Dogliotti, Mechanisms of dealing with DNA damage in terminally differentiated cells, *Mutat. Res. - Fundam. Mol. Mech. Mutagen.* (2010) 38–44. doi:10.1016/j.mrfmmm.2009.11.003.
- [83] C.J. Lord, A. Ashworth, The DNA damage response and cancer therapy, *Nature.* 481 (2012) 287–294. doi:10.1038/nature10760.
- [84] F.M. Hsu, S. Zhang, B.P. Chen, Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment, *Transl Cancer Res.* 1 (2012) 22–34. doi:10.3978/j.issn.2218-676X.2012.04.01.
- [85] S.P. Jackson, The DNA-damage response: new molecular insights and new approaches to cancer therapy., *Biochem. Soc. Trans.* 37 (2009) 483–94. doi:10.1042/BST0370483.
- [86] N. Tonotsuka, Y. Hosoi, S. Miyazaki, G. Miyata, K. Sugawara, T. Mori, N. Ouchi, S. Satomi, Y. Matsumoto, K. Nakagawa, K. Miyagawa, T. Ono, Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium, *Int. J. Mol. Med.* 18 (2006) 441–7.
- [87] Y. Hosoi, T. Watanabe, K. Nakagawa, Y. Matsumoto, A. Enomoto, A. Morita, H. Nagawa, N. Suzuki, Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer, *Int J Oncol.* 25 (2004) 461–8.
- [88] S.W. Lee, K.J. Cho, J.H. Park, Y.K. Sang, Y.N. Soon, B.J. Lee, S.B. Kim, S.H. Choi, H.K. Jong, D.A. Seung, S.S. Seong, K.C. Eun, E. Yu, Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma, *Int. J. Radiat. Oncol. Biol. Phys.* 62 (2005) 1451–7. doi:10.1016/j.ijrobp.2004.12.049.
- [89] H.S. Lee, H.K. Yang, W.H. Kim, G. Choe, Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers, *Cancer Res Treat.* 37 (2005) 98–102. doi:10.4143/crt.2005.37.2.98.

- [90] Y. Hao, X. Hu, Y. Liu, B. Jin, H. Wen, K. Hou, J. Kang, The expression of ERCC1, DNA-PKcs protein and the relation to prognosis in non-small cell lung cancer, *Chinese J. Lung Cancer*. 11 (2008) 226–30. doi:10.3779/j.issn.1009-3419.2008.02.009.
- [91] S. Hu, Y. Qu, X. Xu, Q. Xu, J. Geng, J. Xu, Nuclear Survivin and Its Relationship to DNA Damage Repair Genes in Non-Small Cell Lung Cancer Investigated Using Tissue Array, *PLoS One*. 8 (2013) e74161. doi:10.1371/journal.pone.0074161.
- [92] E. Kotula, N. Berthault, C. Agrario, M.-C. Lienafa, A. Simon, F. Dingli, D. Loew, V. Sibut, S. Saule, M. Dutreix, DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion., *Cell Cycle*. 14 (2015) 1961–72. doi:10.1080/15384101.2015.1026522.
- [93] S.F. Yap, C.S.K. Boo, S.L.E. Loong, R. Baskar, Normal sequence and activity but reduced levels of DNA-Pkcs in human lymphoblastic cells implicate impaired protein stability with radiosensitive phenotype, *J. Cancer*. 4 (2013) 606–613. doi:10.7150/jca.6453.
- [94] M. Someya, K. Sakata, Y. Matsumoto, R.P. Kamdar, M. Kai, M. Toyota, M. Hareyama, The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer., *Br. J. Cancer*. 104 (2011) 1724–1729. doi:10.1038/bjc.2011.158.
- [95] M. Someya, K. Sakata, Y. Matsumoto, H. Yamamoto, M. Monobe, H. Ikeda, K. Ando, Y. Hosoi, N. Suzuki, M. Hareyama, Association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer., *Carcinogenesis*. 27 (2006) 117–22. doi:10.1093/carcin/bgi175.
- [96] S.-Y. Wang, L. Peng, C.-P. Li, A.-P. Li, J.-W. Zhou, Z.-D. Zhang, Q.-Z. Liu, Genetic variants of the XRCC7 gene involved in DNA repair and risk of human bladder cancer., *Int. J. Urol*. 15 (2008) 534–9. doi:10.1111/j.1442-2042.2008.02049.x.
- [97] M.S. Luijsterburg, H. van Attikum, Chromatin and the DNA damage response: the cancer connection, *Mol. Oncol*. 5 (2011) 349–367. doi:10.1016/j.molonc.2011.06.001.
- [98] J.M. Munck, M.A. Batey, Y. Zhao, H. Jenkins, C.J. Richardson, C. Cano, M. Tavecchio, J. Barbeau, J. Bardos, L. Cornell, R.J. Griffin, K. Menear, A. Slade, P. Thommes, N.M.B. Martin, D.R. Newell, G.C.M. Smith, N.J. Curtin, Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K., *Mol. Cancer Ther.* (2012). doi:10.1158/1535-7163.MCT-11-0535.
- [99] G.G. Sharma, S. So, A. Gupta, R. Kumar, C. Cayrou, N. Avvakumov, U. Bhadra, R.K. Pandita, M.H. Porteus, D.J. Chen, J. Cote, T.K. Pandita, MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair., *Mol. Cell. Biol*. 30 (2010) 3582–95. doi:10.1128/MCB.01476-09.
- [100] J.C. Chuang, P.A. Jones, Epigenetics and microRNAs, *Pediatr. Res*. 61 (2007). doi:10.1203/pdr.0b013e3180457684.
- [101] S. Sharma, T.K. Kelly, P.A. Jones, Epigenetics in cancer, *Carcinogenesis*. 31 (2009) 27–36. doi:10.1093/carcin/bgp220.
- [102] C. Ladd-Acosta, A.P. Feinberg, Cancer epigenomics, in: *Epigenomics*, 2009: pp. 385–395. doi:10.1007/978-1-4020-9187-2\_21.
- [103] V. Liyanage, J. Jarmasz, N. Murugesan, M. Del Bigio, M. Rastegar, J. Davie, DNA Modifications: Function and Applications in Normal and Disease States, *Biology (Basel)*. 3 (2014) 670–723. doi:10.3390/biology3040670.
- [104] J.K. Kim, M. Samaranayake, S. Pradhan, Epigenetic mechanisms in mammals, *Cell. Mol. Life Sci*. 66 (2009) 596–612. doi:10.1007/s00018-008-8432-4.

- [105] H.-C. Tsai, S.B. Baylin, Cancer epigenetics: linking basic biology to clinical medicine, *Cell Res.* 21 (2011) 502–517. doi:10.1038/cr.2011.24.
- [106] N.A. Barlev, V. Poltoratsky, T. Owen-Hughes, C. Ying, L. Liu, J.L. Workman, S.L. Berger, Repression of GCN5 histone acetyltransferase activity via bromodomain-mediated binding and phosphorylation by the Ku-DNA-dependent protein kinase complex, *Mol Cell Biol.* 18 (1998) 1349–1358.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9488450](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9488450).
- [107] J.D. Moore, J.E. Krebs, Histone modifications and DNA double-strand break repair, *Biochem. Cell Biol.* 82 (2004) 446–452. doi:10.1139/o04-034.
- [108] H. van Attikum, S.M. Gasser, Crosstalk between histone modifications during the DNA damage response, *Trends Cell Biol.* 19 (2009) 207–217. doi:10.1016/j.tcb.2009.03.001.
- [109] E.J. Park, D.W. Chan, J.H. Park, M.A. Oettinger, J. Kwon, DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner, *Nucleic Acids Res.* 31 (2003) 6819–6827. doi:10.1093/nar/gkg921.
- [110] L. Wang, L. Xie, S. Ramachandran, Y.Y. Lee, Z. Yan, L. Zhou, K. Krajewski, F. Liu, C. Zhu, D.J. Chen, B.D. Strahl, J. Jin, N. V. Dokholyan, X. Chen, Non-canonical Bromodomain within DNA-PKcs Promotes DNA Damage Response and Radioresistance through Recognizing an IR-Induced Acetyl-Lysine on H2AX, *Chem. Biol.* 22 (2015) 849–861. doi:10.1016/j.chembiol.2015.05.014.
- [111] D. Chowdhury, M.-C. Keogh, H. Ishii, C.L. Peterson, S. Buratowski, J. Lieberman, gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair., *Mol. Cell.* 20 (2005) 801–809. doi:10.1016/j.molcel.2005.10.003.
- [112] X. Jiang, Y. Sun, S. Chen, K. Roy, B.D. Price, The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM, *J. Biol. Chem.* 281 (2006) 15741–15746. doi:10.1074/jbc.M513172200.
- [113] H. Lans, J.A. Marteijn, W. Vermeulen, ATP-dependent chromatin remodeling in the DNA-damage response, *Epigenetics Chromatin.* 5 (2012) 4. doi:10.1186/1756-8935-5-4.
- [114] R.A. McCord, E. Michishita, T. Hong, E. Berber, L.D. Boxer, R. Kusumoto, S. Guan, X. Shi, O. Gozani, A.L. Burlingame, V.A. Bohr, K.F. Chua, SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair., *Aging (Albany. NY).* 1 (2009) 109–121. doi:10.18632/aging.100011.
- [115] Y. Jiang, X. Qian, J. Shen, Y. Wang, X. Li, R. Liu, Y. Xia, Q. Chen, G. Peng, S.Y. Lin, Z. Lu, Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation, *Nat. Cell Biol.* 17 (2015) 1158–1168. doi:10.1038/ncb3209.
- [116] L.C. Young, D.W. McDonald, M.J. Hendzel, Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following  $\gamma$ -irradiation., *J. Biol. Chem.* 288 (2013) 21376–88. doi:10.1074/jbc.M113.491514.
- [117] N. Nair, M. Shoaib, C.S. Sørensen, Chromatin dynamics in genome stability: Roles in suppressing endogenous DNA damage and facilitating DNA repair, *Int. J. Mol. Sci.* 18 (2017). doi:10.3390/ijms18071486.
- [118] Y. Wang, H. Sun, J. Wang, H. Wang, L. Meng, C. Xu, M. Jin, B. Wang, Y. Zhang, Y. Zhang, T. Zhu, DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity, *Cell Death Dis.* 7 (2016) e2316. doi:10.1038/cddis.2016.198.
- [119] H. Liu, M. Galka, E. Mori, X. Liu, Y.F. Lin, R. Wei, P. Pittock, C. Voss, G. Dhami, X. Li,

- M. Miyaji, G. Lajoie, B. Chen, S.S. Li, A method for systematic mapping of protein lysine methylation identifies functions for HP1beta in DNA damage response, *Mol Cell*. 50 (2013) 723–735. doi:10.1016/j.molcel.2013.04.025.
- [120] A. Cristini, J.H. Park, G. Capranico, G. Legube, G. Favre, O. Sordet, DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions, *Nucleic Acids Res.* 44 (2016) 1161–1178. doi:10.1093/nar/gkv1196.
- [121] J. Dabin, A. Fortuny, S.E. Polo, Epigenome Maintenance in Response to DNA Damage, *Mol. Cell*. 62 (2016) 712–727. doi:10.1016/j.molcel.2016.04.006.
- [122] K. Ha, G.E. Lee, S.S. Pali, K.D. Brown, Y. Takeda, K. Liu, K.N. Bhalla, K.D. Robertson, Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery, *Hum. Mol. Genet.* 20 (2011) 126–140. doi:10.1093/hmg/ddq451.
- [123] H.J. Kim, J.H. Kim, E.K. Chie, D.Y. Park, I.A. Kim, I.H. Kim, DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity, *Radiat. Oncol.* 7 (2012) 39. doi:10.1186/1748-717X-7-39.
- [124] J.A. Meador, Y. Su, J.L. Ravanat, A.S. Balajee, DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine, *Carcinogenesis*. 31 (2010) 184–191. doi:10.1093/carcin/bgp284.
- [125] F. Wahid, A. Shehzad, T. Khan, Y.Y. Kim, MicroRNAs: Synthesis, mechanism, function, and recent clinical trials, *Biochim. Biophys. Acta - Mol. Cell Res.* 1803 (2010) 1231–1243. doi:10.1016/j.bbamcr.2010.06.013.
- [126] L.-A. MacFarlane, P. R. Murphy, MicroRNA: Biogenesis, Function and Role in Cancer, *Curr. Genomics*. 11 (2010) 537–561. doi:10.2174/138920210793175895.
- [127] Y. Cai, X. Yu, S. Hu, J. Yu, A Brief Review on the Mechanisms of miRNA Regulation, *Genomics, Proteomics Bioinforma.* 7 (2009) 147–154. doi:10.1016/S1672-0229(08)60044-3.
- [128] N. Li, Y. Ma, L. Ma, Y. Guan, L. Ma, D. Yang, MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC, *Cell Biol. Int.* 41 (2017) 622–629. doi:10.1002/cbin.10765.
- [129] X. Han, X. Xue, H. Zhou, G. Zhang, A molecular view of the radioresistance of gliomas, *Oncotarget*. 8 (2017) 100931–100941. doi:10.18632/oncotarget.21753.
- [130] D. Yan, W.L. Ng, X. Zhang, P. Wang, Z. Zhang, Y.Y. Mo, H. Mao, C. Hao, J.J. Olson, W.J. Curran, Y. Wang, Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation, *PLoS One*. 5 (2010). doi:10.1371/journal.pone.0011397.
- [131] H. Hu, Y. He, Y. Wang, W. Chen, B. Hu, Y.L. Gu, micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine, *Biochem. Biophys. Res. Commun.* 483 (2017) 725–731. doi:10.1016/j.bbrc.2016.12.074.
- [132] S. Chen, H. Wang, W.L. Ng, W.J. Curran, Y. Wang, Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level, *Int. J. Radiat. Oncol. Biol. Phys.* 81 (2011) 1524–1529. doi:10.1016/j.ijrobp.2011.05.031.
- [133] J.-Y. Jeong, H. Kang, T.H. Kim, G. Kim, J.-H. Heo, A.-Y. Kwon, S. Kim, S. Jung, H.-J. An, MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3, *Cancer Lett.* 386 (2017) 168–178. doi:10.1016/j.canlet.2016.11.017.
- [134] Y. Li, W. Han, T.T. Ni, L. Lu, M. Huang, Y. Zhang, H. Cao, H.Q. Zhang, W. Luo, H. Li,

- Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells, *Oncol. Rep.* 33 (2015) 2821–2828. doi:10.3892/or.2015.3884.
- [135] D. Rodin, F.M. Knaul, T.Y. Lui, M. Gospodarowicz, Radiotherapy for breast cancer: The predictable consequences of an unmet need, *Breast.* 29 (2016) 120–122. doi:10.1016/j.breast.2016.07.006.
- [136] P. Chinnaiyan, G. Vallabhaneni, E. Armstrong, S.-M. Huang, P.M. Harari, Modulation of radiation response by histone deacetylase inhibition., *Int. J. Radiat. Oncol. Biol. Phys.* 62 (2005) 223–229. doi:10.1016/j.ijrobp.2004.12.088.
- [137] F. Zhang, T. Zhang, Z. Teng, R. Zhang, J. Wang, Q. Mei, Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells, *Cancer Biol Ther.* 8 (2009). [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19270532](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19270532).
- [138] S. Minucci, P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer., *Nat. Rev. Cancer.* 6 (2006) 38–51. doi:10.1038/nrc1779.
- [139] H. Ogiwara, a Ui, a Otsuka, H. Satoh, I. Yokomi, S. Nakajima, a Yasui, J. Yokota, T. Kohno, Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors., *Oncogene.* 30 (2011) 2135–2146. doi:10.1038/onc.2010.592;
- [140] M. Toulany, K.-J. Lee, K.R. Fattah, Y.-F. Lin, B. Fehrenbacher, M. Schaller, B.P. Chen, D.J. Chen, H.P. Rodemann, Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs-Dependent DNA Double-Strand Break Repair, *Mol. Cancer Res.* (2012). doi:10.1158/1541-7786.MCR-11-0592.
- [141] M. Stucki, J.A. Clapperton, D. Mohammad, M.B. Yaffe, S.J. Smerdon, S.P. Jackson, MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks, *Cell.* (2005). doi:10.1016/j.cell.2005.09.038.
- [142] B.B. Olsen, T.H. Svenstrup, B. Guerra, Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells, *Int. J. Oncol.* (2012). doi:10.3892/ijo.2012.1635.
- [143] B.-J. Pyun, H.R. Seo, H.-J. Lee, Y.B. Jin, E.-J. Kim, N.H. Kim, H.S. Kim, H.W. Nam, J.I. Yook, Y.-S. Lee, Mutual regulation between DNA-PKcs and Snail1 leads to increased genomic instability and aggressive tumor characteristics., *Cell Death Dis.* (2013). doi:10.1038/cddis.2013.43.
- [144] G.Y. Kang, B.J. Pyun, H.R. Seo, Y.B. Jin, H.J. Lee, Y.J. Lee, Y.S. Lee, Inhibition of snail1-DNA-PKcs protein-protein interface sensitizes cancer cells and inhibits tumor metastasis, *J. Biol. Chem.* 288 (2013) 32506–32516. doi:10.1074/jbc.M113.479840.
- [145] J.F. Goodwin, V. Kothari, J.M. Drake, S. Zhao, E. Dylgjeri, J.L. Dean, M.J. Schiewer, C. McNair, J.K. Jones, A. Aytes, M.S. Magee, A.E. Snook, Z. Zhu, R.B. Den, R.C. Birbe, L.G. Gomella, N.A. Graham, A.A. Vashisht, J.A. Wohlschlegel, T.G. Graeber, R.J. Karnes, M. Takhar, E. Davicioni, S.A. Tomlins, C. Abate-Shen, N. Sharifi, O.N. Witte, F.Y. Feng, K.E. Knudsen, DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis, *Cancer Cell.* 28 (2015) 97–113. doi:10.1016/j.ccell.2015.06.004.
- [146] F. Bouquet, M. Ousset, D. Biard, F. Fallone, S. Dauvillier, P. Frit, B. Salles, C. Muller, A

- DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia, *J. Cell Sci.* 124 (2011) 1943–1951. doi:10.1242/jcs.078030.
- [147] E. Madan, R. Gogna, U. Pati, p53 Ser15 phosphorylation disrupts the p53-RPA70 complex and induces RPA70-mediated DNA repair in hypoxia., *Biochem. J.* 443 (2012) 811–20. doi:10.1042/BJ20111627.
  - [148] K.E. Gurley, R. Moser, Y. Gu, P. Hasty, C.J. Kemp, DNA-PK suppresses a p53-independent apoptotic response to DNA damage., *EMBO Rep.* 10 (2009) 87–93. doi:10.1038/embor.2008.214.
  - [149] A. Finzel, A. Grybowski, J. Strasen, E. Cristiano, A. Loewer, Hyper-activation of ATM upon DNA-PKcs inhibition modulates p53 dynamics and cell fate in response to DNA damage., *Mol. Biol. Cell.* 27 (2016) 2360–2367. doi:10.1091/mbc.E16-01-0032.
  - [150] R. Hill, P.A. Madureira, D.M. Waisman, P.W.K. Lee, R. Hill, P.A. Madureira, D.M. Waisman, P.W.K. Lee, DNA-PKcs binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death, *Oncotarget.* (2011).
  - [151] C. Beskow, J. Skikuniene, a Holgersson, B. Nilsson, R. Lewensohn, L. Kanter, K. Viktorsson, Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86., *Br. J. Cancer.* 101 (2009) 816–821. doi:10.1038/sj.bjc.6605201.
  - [152] X. Tian, G. Chen, H. Xing, D. Weng, Y. Guo, D. Ma, The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa, *Oncol. Rep.* 18 (2007) 927–32.
  - [153] C. Beskow, J. Skikuniene, A. Holgersson, B. Nilsson, R. Lewensohn, L. Kanter, K. Viktorsson, Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86., *Br. J. Cancer.* 101 (2009) 8116–21. doi:10.1038/sj.bjc.6605201.
  - [154] P. Bouchaert, S. Guerif, C. Debais, J. Irani, G. Fromont, DNA-PKcs expression predicts response to radiotherapy in prostate cancer, *Int. J. Radiat. Oncol. Biol. Phys.* 84 (2012) 1179–1185. doi:10.1016/j.ijrobp.2012.02.014.
  - [155] K. Dittmann, C. Mayer, H.P. Rodemann, Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity, in: *Radiother. Oncol.*, 2005: pp. 157–61. doi:10.1016/j.radonc.2005.06.022.
  - [156] B. Pinel, M. Duchesne, J. Godet, S. Milin, A. Berger, M. Wager, L. Karayan-Tapon, Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide, *J. Neurooncol.* 132 (2017) 287–294. doi:10.1007/s11060-016-2367-7.
  - [157] R. Thijssen, J. Ter Burg, B. Garrick, G.G.W. van Bochove, J.R. Brown, S.M. Fernandes, M.S. Rodríguez, J. Michot, M. Hallek, B. Eichhorst, H.C. Reinhardt, J. Bendell, I.A.M. Derks, R.J.W. van Kampen, K. Hege, M.J. Kersten, T. Trowe, E.H. Filvaroff, E. Eldering, A.P. Kater, J. Burg, B. Garrick, G.G.W. Van Bochove, J.R. Brown, S.M. Fernandes, J. Michot, M. Hallek, B. Eichhorst, H.C. Reinhardt, J. Bendell, I.A.M. Derks, R.J.W. Van Kampen, K. Hege, M. Jos, T. Trowe, E.H. Filvaroff, E. Eldering, A.P. Kater, J. Ter Burg, B. Garrick, G.G.W. van Bochove, J.R. Brown, S.M. Fernandes, M.S. Rodríguez, J. Michot, M. Hallek, B. Eichhorst, H.C. Reinhardt, J. Bendell, I.A.M. Derks, R.J.W. van Kampen, K. Hege, M.J. Kersten, T. Trowe, E.H. Filvaroff, E. Eldering, A.P. Kater, Dual TORK / DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic

- leukemia, *Blood*. 128 (2016) 574–584. doi:10.1182/blood-2016-02-700328.
- [158] M.T. Niazi, G. Mok, M. Heravi, L. Lee, T. Vuong, R. Aloyz, L. Panasci, T. Muanza, Effects of DNA-dependent protein kinase inhibition by NU7026 on DNA repair and cell survival in irradiated gastric cancer cell line N87, *Curr. Oncol.* 21 (2014) 91–96. doi:10.3747/co.21.1509.
- [159] H. Tarazi, E. Saleh, R. El-Awady, In-silico screening for DNA-dependent protein kinase (DNA-PK) inhibitors: Combined homology modeling, docking, molecular dynamic study followed by biological investigation, *Biomed. Pharmacother.* 83 (2016) 693–703. doi:10.1016/j.biopha.2016.07.044.
- [160] V.C. George, H.P.V. Rupasinghe, Apple flavonoids suppress carcinogens-induced DNA damage in normal human bronchial epithelial cells, (n.d.) 1–34.
- [161] J.N. Sarkaria, R.S. Tibbetts, E.C. Busby, A.P. Kennedy, D.E. Hill, R.T. Abraham, Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin, *Cancer Res.* (1998).
- [162] T. Lin, N.K. Mak, M.S. Yang, MAPK regulate p53-dependent cell death induced by benzo[a]pyrene: Involvement of p53 phosphorylation and acetylation, *Toxicology*. 247 (2008) 145–153. doi:10.1016/j.tox.2008.02.017.
- [163] H. Osada, Y. Tatematsu, N. Sugito, Y. Horio, T. Takahashi, Histone modification in the TGF $\beta$ 2 gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines, *Mol. Carcinog.* 44 (2005) 233–241. doi:10.1002/mc.20135.
- [164] T.T. Paull, E.P. Rogakou, V. Yamazaki, C.U. Kirchgesner, M. Gellert, W.M. Bonner, A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage, *Curr. Biol.* 10 (2000) 886–895. doi:10.1016/S0960-9822(00)00610-2.
- [165] S.-M.M. Maira, F. Stauffer, C. Schnell, C. García-Echeverría, PI3K inhibitors for cancer treatment: where do we stand?, *Biochem. Soc. Trans.* (2009). doi:10.1042/BST0370265.
- [166] R. Wang, X. Zheng, L. Zhang, B. Zhou, H. Hu, Z. Li, L. Zhang, Y. Lin, X. Wang, Histone H4 expression is cooperatively maintained by IKK $\beta$  and Akt1 which attenuates cisplatin-induced apoptosis through the DNA-PK/RIP1/IAPs signaling cascade, *Sci. Rep.* 7 (2017). doi:10.1038/srep41715.
- [167] E. Willmore, S. De Caux, N.J. Sunter, M.J. Tilby, G.H. Jackson, C.A. Austin, B.W. Durkacz, A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia, *Blood*. (2004). doi:10.1182/blood-2003-07-2527.
- [168] S.J. Veuger, N.J. Curtin, C.J. Richardson, G.C.M. Smith, Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADP-ribose) polymerase-1, *Cancer Res.* (2003).
- [169] S. Durant, P. Karran, Vanillins - A novel family of DNA-PK inhibitors, *Nucleic Acids Res.* (2003). doi:10.1093/nar/gkg753.
- [170] T. Hisatomi, N. Sueoka-Aragane, A. Sato, R. Tomimasu, M. Ide, A. Kurimasa, K. Okamoto, S. Kimura, E. Sueoka, NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II $\alpha$  and DNA-dependent protein kinase., *Blood*. (2011). doi:10.1182/blood-2010-02-270439.
- [171] S. Demyanets, C. Kaun, K. Rychli, S. Pfaffenberger, S.P. Kastl, P.J. Hohensinner, G. Rega, K.M. Katsaros, T. Afonyushkin, V.N. Bochkov, M. Paireder, I. Huk, G. Maurer, K. Huber, J. Wojta, Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and

- STAT1/STAT3-dependent pathways and is attenuated by interferon- $\gamma$ , *Basic Res. Cardiol.* (2011). doi:10.1007/s00395-010-0141-0.
- [172] B. Apsel, J.A. Blair, B. Gonzalez, T.M. Nazif, M.E. Feldman, B. Aizenstein, R. Hoffman, R.L. Williams, K.M. Shokat, Z.A. Knight, Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases., *Nat. Chem. Biol.* (2008). doi:10.1038/nchembio.117.
- [173] D.S. Mortensen, S.M. Perrin-Ninkovic, G. Shevlin, J. Elsner, J. Zhao, B. Whitefield, L. Tehrani, J. Sapienza, J.R. Riggs, J.S. Parnes, P. Papa, G. Packard, B.G.S. Lee, R. Harris, M. Correa, S. Bahmanyar, S.J. Richardson, S.X. Peng, J. Leisten, G. Khambatta, M. Hickman, J.C. Gamez, R.R. Bisonette, J. Apuy, B.E. Cathers, S.S. Canan, M.F. Moghaddam, H.K. Raymon, P. Worland, R.K. Narla, K.E. Fultz, S. Sankar, Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115, *J. Med. Chem.* (2015). doi:10.1021/acs.jmedchem.5b00627.
- [174] G.C.M. Smith, M.J. O'Connor, N.M.B. Martin, Targeted cancer therapies based on the inhibition of DNA strand break repair, *Oncogene.* (2007). doi:10.1038/sj.onc.1210879.
- [175] D. Davidson, L. Amrein, L. Panasci, R. Aloyz, Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond, *Front. Pharmacol.* 4 JAN (2014). doi:10.3389/fphar.2013.00005.
- [176] J.W. Shay, W.E. Wright, Telomerase therapeutics for cancer: challenges and new directions, *Nat. Rev. Drug Discov.* (2006) 1–8. doi:10.1038/nrd2081.
- [177] H. Xiong, R.J. Lee, E.B. Haura, J.G. Edwards, W.S. Dynan, S. Li, Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit, *Int. J. Radiat. Oncol. Biol. Phys.* 83 (2012) 1023–1030. doi:10.1016/j.ijrobp.2011.08.039.
- [178] C.H. Kim, S.J. Park, S.H. Lee, A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation, *J Pharmacol Exp Ther.* 303 (2002) 753–759. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12388662](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12388662).
- [179] J. An, Q.Z. Xu, J.L. Sui, B. Bai, P.K. Zhou, Downregulation of c-myc protein by siRNA-mediated silencing of DNA-PKcs in HeLa cells, *Int. J. Cancer.* 117 (2005) 531–537. doi:10.1002/ijc.21093.
- [180] G.F. Claassen, S.R. Hann, A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor  $\beta$ -induced cell-cycle arrest, *Proc. Natl. Acad. Sci.* 97 (2000) 9498–9503. doi:10.1073/pnas.150006697.
- [181] Y. Peng, Q. Zhang, H. Nagasawa, R. Okayasu, H.L. Liber, J.S. Bedford, Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation, *Cancer Res.* 62 (2002) 6400–6404. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12438223](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12438223).
- [182] W. Li, W. Jian, X. Xiaoping, L. Yingfeng, X. Tao, X. Xiaoyan, Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein, *Int. J. Gynecol. Cancer.* 16 (2006) 1620–1630. doi:10.1111/j.1525-1438.2006.00636.x.

- [183] A.I. Belenkov, J.P. Paiement, L.C. Panasci, B.P. Monia, T.Y.K. Chow, An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents, *Cancer Res.* 62 (2002) 5888–5896.
- [184] S. Daido, A. Yamamoto, K. Fujiwara, R. Sawaya, S. Kondo, Y. Kondo, Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy, *Cancer Res.* 65 (2005) 4368–4375. doi:10.1158/0008-5472.CAN-04-4202.
- [185] S. Omori, Y. Takiguchi, A. Suda, T. Sugimoto, H. Miyazawa, N. Tanabe, K. Tatsumi, H. Kimura, P.E. Pardington, F. Chen, D.J. Chen, T. Kuriyama, Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line, *DNA Repair.* 1 (2002) 299–310. doi:S156878640200006X [pii].
- [186] P. Bouchaert, S. Guerif, C. Debais, J. Irani, G. Fromont, DNA-PKcs expression predicts response to radiotherapy in prostate cancer, *Int. J. Radiat. Oncol. Biol. Phys.* 84 (2012) 1179–85. doi:10.1016/j.ijrobp.2012.02.014.
- [187] B. Zheng, J.-H. Mao, X.-Q. Li, L. Qian, H. Zhu, D. Gu, X. Pan, Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2 $\alpha$  expression and cell proliferation., *Sci. Rep.* 6 (2016) 29415. doi:10.1038/srep29415.
- [188] E. Willmore, S.L. Elliott, T. Mainou-fowler, G.P. Summerfield, G.H. Jackson, F. O'Neill, C. Lowe, A. Carter, R. Harris, A.R. Pettitt, C. Cano-soumillac, R.J. Griffin, I.G. Cowell, C.A. Austin, B.W. Durkacz, F.O. Neill, C. Lowe, A. Carter, R. Harris, A.R. Pettitt, C. Cano-soumillac, R.J. Griffin, I.G. Cowell, C.A. Austin, B.W. Durkacz, F. O'Neill, DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia., *Clin. Cancer Res.* 14 (2008) 3984–92. doi:10.1158/1078-0432.CCR-07-5158.
- [189] J.Y. Xu, S. Lu, X.Y. Xu, S.L. Hu, B. Li, R.X. Qi, L. Chen, J.Y. Chang, Knocking down nucleolin expression enhances the radiosensitivity of non-small cell lung cancer by influencing dna-pkcs activity, *Asian Pacific J. Cancer Prev.* 16 (2015) 3301–3306. doi:10.7314/APJCP.2015.16.8.3301.
- [190] S.S. Yan, L. Liu, Z.G. Liu, M.S. Zeng, L.B. Song, Y.F. Xia, [Expression and clinical significance of DNA-PKcs in nasopharyngeal carcinoma], *Ai Zheng.* 27 (2008) 979–983. doi:1000-467X200809979 [pii].

**Table 1. Differential expression levels of DNA-PK in normal and cancer cells**

<b>Tissue/cell types</b>	<b>DNA-PK expression levels</b>	<b>Specificity</b>	<b>References</b>
<i>Normal cells</i>			
Neural cells	High expression	Brain cortex and autonomous nervous system	[78]
Reproductive tissues	High expression	Testis	[78]
	Moderate expression	Ovary and prostate	
Epithelial cells	Moderate expression	Colon, pancreas and kidney	[78]
Breast tissues	High expression	Lactating breast tissues	[78]
	Less to no expression	Resting breast tissues	
<i>Cancer Cells</i>			
Esophageal cancer	Differential expression	Difficulty in prediction of radio or chemo-sensitivity of tumour	[86]
Colorectal carcinoma	High expression	Potential biomarker for clinical assessment of pathogenesis and prognosis of carcinoma	[87]
Gastric cancer	Low expression	Poor patient survival	[89]
Glioma	High expression	Better response to radiotherapy and chemotherapy	[92]
Cervical cancer	High expression	Resistant to radiation treatment	[152]
Prostate cancer	High expression	Reduced response to standard radiation therapy	[186]

Human renal cell carcinoma	Over expression	Target for renal cell carcinoma intervention	[187]
B-cell chronic lymphocytic leukemia	High expression	Short survival and chemo- resistance	[188]
Non small lung cancer	High expression	Radio-resistance	[189]
Nasopharyngeal carcinoma	High expression	Poor survival	[190]

---

## Figure legends

**Fig. 1. DNA-PK in NHEJ mechanism.** The process of NHEJ starts with the recognition and binding of Ku70/80 sub-units to broken DNA ends which function as docking sites for other proteins including DNA-PKcs. DNA-PKcs recruitment to Ku70/80 complex dimerizes to form a synaptic complex which acts as scaffold proteins for localization of other repair proteins to the damaged site of DNA. Autophosphorylation of DNA-PK at ABCDE region opens the DNA ends for further processing by Artemis protein which was recruited and activated by DNA-PK. DNA-PK also recruits and mediates the phosphorylation of DNA polymerase  $\lambda$  for gap filling during DNA synthesis. Upon autophosphorylation of DNA-PK at PQR region along with ABCDE protein, leads to dissociation of DNA-PKcs from the Ku-DNA complex. As an end process, Lig4-XRCC4 complex mediates efficient DNA ligation with the help of cernunnos/XRCC4-like factor (XLF) and repairs the DNA DSBs successfully.

## **Fig. 2 The role of DNA-PK in normal cells (A) and cancer cells (B).**

**A. Normal cells.** DNA-PK is essential for maintaining genomic stability by regulating DNA repair, chromosome segregation, and telomere capping. (i) DNA-PK is a critical component of NHEJ pathway that is required for repairing damaged DNA and for generation of B and T cells by V(D)J recombination along with other proteins including Artemis, XRCC4, and Lig4. (ii) In mitosis, phosphorylated DNA-PKcs colocalizes with polo-like kinase 1 (PLK1) at the centrosomes and kinetochores, for proper chromosome segregation with an accumulation of midbody for controlling cytokinesis. (iii) During telomere capping, heterogeneous ribonucleoprotein A1 (hnRNP-A1) gets phosphorylated by DNA-PKcs and promotes the replication protein A (RPA) to protect telomeres 1 (POT1), by switching telomeric 3' single-

strands to form a cap over newly replicated telomeres. (iv) DNA-PK also plays an important role in B/T cell generation and viral infection-mediated innate immunity. DNA-PK functions as a pattern recognition receptor to activate innate immunity. It binds to cytoplasmic DNA and activates IFN regulatory factor 3 (IRF-3)-dependent innate immune response to trigger transcription of type I interferons (IFN).

**B. Cancer cells.** In cancer cells, increased expression of DNA-PK regulates specific pro-tumorigenic pathways including genomic instability, hypoxia, metabolism and inflammatory responses. (i) DNA-PK is directly involved in the transcriptional regulation of c-Myc, c-Jun and p53, leading to tumor cell survival and proliferation. Under hypoxic conditions, DNA-PK is activated independent of DNA repair pathway and regulates HIF $\alpha$ , thereby activating various pro-tumorigenic genes. (ii) DNA-PK contributes to EMT, an essential step in tumor metastasis, by regulating zinc finger transcription factor snail. (iii) DNA-PK also maintains the tumor microenvironment by controlling the secretion of several proteins like MMP-8.-9, SERPINA3 etc. (iv) Moreover, DNA-PKcs regulates mitotic spindle organization via the Chk2–BRCA1 signaling pathway and the loss of DNA-PKcs will prevent the activation of Chk2–BRCA1 signaling pathway, leading to chromosomal instability.

**Fig. 3. Interplay between DNA-PK and epigenetic modifications.** DNA DSBs caused by ionizing radiation or camptothecin initiates the phosphorylation of histone H2AX protein to generate  $\gamma$ -H2AX that can initiate histone modifications. DNA-PK can be affected by the function of different histone modifiers, such as acetyl transferase (HAT), MOF and Tip60 during DNA repair process. MOF specifically acetylates histone H4 at lysine 16 that are involved in chromatin modification, to induce accumulation of DNA-PK at the damaged site, whereas Tip60

induces the activation of DNA-PKcs kinase activity. The indirect interplay between histone demethylase and DNA-PK were also found to be involved in DDR process. DNA-PK indirectly inhibits the histone demethylase activity of KDM2B by recruiting its accumulation at damaged site. This inhibition by the phosphorylated fumarase by DNA-PK, interacts with H2A.Z at DSB regions and results in local generation of fumarate to inhibit KDM2B. DNA-PK is also involved in histone ubiquitination by promoting H2AX and H2A monoubiquitination which are essential for the recruitment of ATM and 53BP1. The modulation in nucleosome packaging with DNA in response to DSBs can also be induced by DNA-PK by its interaction with ATP-dependent chromatin remodeling factors such as ALC1, to catalyze nucleosome sliding through its interaction with PARP. These major alterations including post-translational histone modifications and ATP-dependent chromatin remodeling factors facilitate the entry of repair proteins to the damage lesions and activate NHEJ/HR repair mechanisms.

**Fig. 4. Various small molecules as DNA PK inhibitors.** Wortmannin (1), LY294002 (2), NU7026 (3), NU7441 (4), OK1035 (5), SU11752 (6), Vanillin (7) & derivatives; 2-nitro (8) and 3-iodo (9), NK314 (10), PI103 (11), PP121 (12), KU-0060648 (13), CC-115 (14).

**FIGURE 1**




FIGURE 2A






FIGURE 2B



**FIGURE 3**



**FIGURE 4**

